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Stepwise evolution of pandrug-
resistance in Klebsiella pneumoniae
Hosam M. Zowawi1,2,3,4,*, Brian M. Forde2,5,*, Mubarak Alfaresi6, Abdulqadir Alzarouni7, 
Yasser Farahat7, Teik-Min Chong8, Wai-Fong Yin8, Kok-Gan Chan8, Jian Li9, 
Mark A. Schembri2,5, Scott A. Beatson2,5 & David L. Paterson1,2
Carbapenem resistant Enterobacteriaceae (CRE) pose an urgent risk to global human health. CRE 
that are non-susceptible to all commercially available antibiotics threaten to return us to the pre-
antibiotic era. Using Single Molecule Real Time (SMRT) sequencing we determined the complete 
genome of a pandrug-resistant Klebsiella pneumoniae isolate, representing the first complete 
genome sequence of CRE resistant to all commercially available antibiotics. The precise location 
of acquired antibiotic resistance elements, including mobile elements carrying genes for the OXA-
181 carbapenemase, were defined. Intriguingly, we identified three chromosomal copies of an 
ISEcp1-blaOXA-181 mobile element, one of which has disrupted the mgrB regulatory gene, accounting 
for resistance to colistin. Our findings provide the first description of pandrug-resistant CRE at 
the genomic level, and reveal the critical role of mobile resistance elements in accelerating the 
emergence of resistance to other last resort antibiotics.
The “golden era” when modern medicine saved lives through antibiotic treatment is under serious threat1. 
In 2013, the Centers for Disease Control and Prevention (CDC) released a landmark report on “Antibiotic 
Resistance Threats2”. Three microorganisms were tagged as posing a threat level of urgent – Clostridium 
difficile, carbapenem-resistant Enterobacteriaceae (CRE) and drug-resistant Neisseria gonorrhoeae2. CRE, 
which include organisms such as Klebsiella pneumoniae and Escherichia coli, are resistant to almost all 
currently available antibiotics. Almost 50% of patients who develop bloodstream infections with these 
organisms die from the infection2. In healthcare settings, carbapenem resistant Enterobacteriaceae have 
increased sharply over the past decade3. Carbapenem resistance is typically mediated by the production 
of beta-lactamases4, and patients with CRE infections are treated with last-resort antibiotics such as 
colistin5.
The CDC and the European Centre for Disease Prevention and Control (ECDC) have jointly devel-
oped definitions for multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria6. 
Pandrug-resistance implies non-susceptibility to all commercially available antibiotics relevant to the 
treatment of a particular bacterial infection. Although there has been an anecdotal report of probable 
pandrug-resistance in K. pneumoniae7, no such isolates have been comprehensively analyzed.
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In this manuscript, we describe the genetic basis of pandrug-resistance in a K. pneumoniae isolate 
using single molecule real-time (SMRT) sequencing. We show that a genetic element conferring resist-
ance to carbapenem antibiotics has been acquired and mobilized, leading to insertional inactivation of a 
gene that results in resistance to colistin. Overall, our analysis provides a comprehensive description of 
a pandrug-resistant K. pneumoniae isolate at the whole genome level.
Results
Case Record. An 87 year old man, hospitalized in the United Arab Emirates in April 2014, was 
found to be colonized with multidrug-resistant Klebsiella pneumoniae. The isolate grew from urine and 
a pre-sacral pressure area but blood cultures were sterile. Susceptibility testing by way of a commercial 
semi-automated method (Vitek, bioMérieux) showed resistance to all antibiotics tested. The urinary iso-
late (strain MS6671) was therefore sent to a reference laboratory for further testing. Other K. pneumoniae 
isolates with this antibiotic resistance phenotype were not detected at the index patient’s hospital.
Pandrug-resistant phenotype of K. pneumoniae MS6671. MS6671 was found to be non-susceptible 
to all antibiotics tested, which includes cephalosporins, penicillins, carbapenems, aztreonam, aminoglyco-
sides, ciprofloxacin, colistin, tetracyclines, tigecycline, chloramphenicol, trimethoprim-sulfamethoxazole 
and fosfomycin (Table 1). Thus, the isolate can truly be described as pandrug-resistant6.
K. pneumoniae MS6671 general genome features. The complete genome of K. pneumoniae 
MS6671 consists of a circular chromosome 5,402,900 base-pairs in length with an average G-C content of 
57%, five circular plasmids and a linear plasmid prophage (Supplementary Table S1). The sequence type 
of the isolate was ST147. The chromosome of MS6671 is highly similar to K. pneumoniae NTUH-k20448; 
a hypervirulent strain associated with liver abscess and meningitis, with most variation attributable to 
differences in their mobile genetic element (MGE) content (Supplementary Figure 1). Further details of 
the complete genome are provided in the Supplementary Results.
Genetic determinants of pandrug-resistance. In order to determine the genetic basis of 
pandrug-resistance, we interrogated the genome to identify acquired and intrinsic resistance genes. 
The majority of acquired antibiotic resistance genes were located on the chromosome, with most 
beta-lactamase and aminoglycoside resistance genes carried within two copies of a class 1 integron or as 
part of mobile elements that incorporate the ISEcp1 insertion sequence (Table 1, Supplementary Table 
S2 and Supplementary Results). Mutations in gyrA and parC that have previously been linked with fluo-
roquinolone resistance (GyrA Ser83Ile and ParC Ser80Ile) were identified9,10. Fosfomycin resistance was 
mediated by a chromosomally encoded copy of fosA11. Mutations in chromosomal genes encoding major 
outer membrane porins (OmpK35 and OmpK36) were also identified. A novel variant of the ompK36 
gene was encoded on the chromosome. The amino acid sequence change is located in loop 3 (L3) of 
the porin, which constitutes the porin channel eyelet12. L3 mutations have previously been associated 
with increased resistance to carbapenems13–15. Additionally, ompK35 has been disrupted by IS insertion. 
Inactivation of ompK35 has been associated with increased resistance to a number of different classes 
of antibiotics, including quinolones and cephalosporins16,17. Genes encoding three beta-lactamases, 
including an extended-spectrum beta-lactamase (ESBL) and a carbapenemase, were detected at different 
genomic locations – blaSHV-36, blaCTX-M-15, blaOXA-181.
Insertional inactivation of mgrB by a carbapenem-resistance element and colistin resist-
ance. OXA-181 is an oxacillinase capable of hydrolysing carbapenems18. Three copies of an 
ISEcp1-blaOXA-181 transposon were identified throughout the chromosome (Fig.  1). One of these inser-
tions has resulted in the inactivation of the mgrB gene, a negative regulator of phoPQ. Insertions in 
mgrB have previously been shown to cause colistin resistance in K. pneumoniae clinical isolates19–21. 
Examination of the DNA flanking the ISEcp1-blaOXA-181 transposons shows that the primary insertion 
site is within MS6671_10430, followed by intra-chromosomal transposition of ISEcp1-blaOXA-181 and a 
37 bp fragment of MS6671_10430 to two other locations in the genome (Fig. 2). The three transposons 
are bracketed by imperfect 14 bp inverted repeats and flanking 5 bp direct repeats (TATCT, TGAAA and 
TATAA), providing direct evidence for their transposition activity (Supplementary Table S3).
In a similar fashion, a single copy of ISEcp1-blaCTX-M-15 has inserted into ompK35, leading to inactiva-
tion this gene (Fig. 1). The ISEcp1-mediated mobilisation and transposition of blaCTX-M-15, blaOXA-181 and 
other clinical relevant beta-lactamase resistance genes, including blaCMY and blaACC, has been reported 
previously22–26.
K. pneumoniae MS6671 contains two copies of a class 1 integron. A class 1 integron was 
identified on the chromosome encoding multiple antibiotic resistance genes (arr-3, aac(6′)-Ib-cr, rmtF, 
catB1) (Fig. 1). These genes result in resistance to rifampin, all aminoglycosides and chloramphenicol. A 
near-identical copy of this integron was also found on one of the six plasmids (Supplementary Figure S2).
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Discussion
This is the first genomic analysis of a pandrug-resistant CRE isolate, as defined by the rigorous 
CDC/ECDC assessment criteria6. With the advantage of long-reads provided by SMRT sequencing we 
were able to identify the genomic context of multiple resistance elements. In contrast to short-read 
technologies, SMRT sequencing allows complex resistance elements to be properly characterized27. 
This technology platform was used to investigate the German E. coli O104:H11 outbreak28 and more 
recently to identify plasmid-borne resistance in a large-scale study of CRE following an outbreak at 
the National Institute for Health Clinical Center29,30. Critically, elucidation of the complete K. pneumo-
niae MS6671 genome using long-read sequencing enabled the context of multiple, identical carbapenem 
resistance elements to be determined. Based on this analysis we propose a model for the development of 
pandrug-resistance in this K. pneumoniae isolate, whereby mobile resistance determinants are responsible 
Antimicrobial Category Antimicrobial Agent
MIC 
(mg/L)
EUCAST 
Interpretation
Genes previously 
associated with resistance†
Aminoglycosides
Gentamicin > 256 R
rmtF, aac(6’)-lb-cr
Tobramycin > 256 R
Amikacin > 256 R
Netilmicin > 256 R
AntiMRSA Cephalosporins Ceftaroline > 32 R blaOXA-181,blaCTX-M-15
Antipseudomonal Penicillins and Beta-
lactamase Inhibitors
Ticarcillin/Clavulanate > 256 R
blaOXA-181
Piperacillin/Tazobactam > 256 R
Carbapenems
Ertapenem > 32 R
blaOXA-181, ompK36 (ins 
aa135–136DT)
Imipenem 4 NS
Meropenem 8 R
Doripenem 4 R
Non-extended Spectrum Cephalosporins
Cefazolin* > 32 R
blaCTX-M-15
Cefuroxime > 256 R
Extended Spectrum Cephalosporins
Ceftriaxone, Cefotaxime > 32 R
blaCTX-M-15Ceftazidime 32 R
Cefepime 32 R
Cephamycins
Cefoxitin* 128 R
blaOXA-181
Cefotetan* 32 NS
Fluoroquinolones Ciprofloxacin > 32 R
gyrA (Ser83Ile), parC 
(Ser80Ile), qnrB ompK35 
inactivation
Folate-pathway Inhibitors Trimethoprim/Sulfamethoxazole 8 R dfrA12, dfrA14‡
Glycylcyclines Tigecycline 4 R acrAB#
Monobactams Aztreonam 32 R blaOXA-181, blaCTX-M-15
Penicillins Ampicillin > 256 R blaSHV-36
Penicillins and Beta-lactamase Inhibitors
Amoxycillin/Clavulanate > 256 R
blaOXA-181
Ampicillin/Sulbactam > 256 R
Phenicols Chlorampenicol 128 R catB1, ompK35 inactivation,
Phosphonic acids Fosfomycin 64 R fosA,
Polymyxins Colistin 128 R mgrB inactivation
Tetracyclines
Tetracycline* 32 R
acrAB#, ompK35 
inactivation, tetCDoxycycline
* 32 R
Minocycline* 32 R
Table 1. Antibiotic resistance in K. pneumoniae MS6671. *Based on the breakpoints of CLSI criteria; 
Polymyxin B MIC was 32 mg/L. †Several additional intrinsic factors, such as efflux pumps and porins, 
which may be involved in multi-drug resistance are also encoded in the genome (Supplementary Table 
S2). ‡Resistance to trimethoprim. No sul genes identified. #Tigecycline resistance has been associated with 
upregulation of acrAB, often resulting from the aberrant expression of ramA and/or ramR. A description of 
the potential mechanism of tigecycline resistance in MS6671 is provided in the Supplementary Results.
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for driving additional resistance. In this example, ISEcp1 carrying the blaOXA-181 carbapenem resistance 
gene has inserted three times in the chromosome, with one event causing colistin resistance by inser-
tional inactivation of mgrB.
ISEcp1-like insertion sequences are the most common genetic element associated with blaCTX-M, 
blaCMY and blaACC genes and have more recently been associated with blaOXA-18122–26,31. By recognizing 
a variety of DNA sequences as right inverted repeats (IRR), ISEcp1s are capable of mobilising adja-
cent genes and inserting at new location32,33. Similar to previous reports on the hydrolytic activities of 
OXA-18118,34,35, elevated MICs for ertapenem, imipenem, meropenem and doripenem were observed for 
Figure 1. Diagram of the pandrug-resistant K. pneumoniae MS6671 chromosome highlighting the 
position and context of mobile genetic elements that harbor antimicrobial resistance genes. The 
chromosome of MS6671 is represented to scale by the black bar with ISEcp1 and integron insertion points 
indicated with red rectangles. Pop-outs display schematic representations of the four ISEcp1 elements which 
harbor beta-lactamase genes (three copies of blaOXA-181 and one copy of blaCTX-M-15) and a class 1 integron 
located on the chromosome of MS6671. Insertion elements are highlighted in yellow. The coordinates of 
each element are indicated above and below the genome bar.
Figure 2. Comparison of ISEcp1-blaOXA-181 transposons from MS6671. Pairwise nucleotide comparison 
of ISEcp1-blaOXA-181 (OXA-181) transposons and flanking genomic regions from K. pneumonaie MS6671. 
ISEcp1 elements are represented by blue rectangles. Protein-coding genes are represented by coloured 
arrows: blaOXA-181 (green); MS6671_10430 encoding a hypothetical protein (red); other (brown). Left and 
right flanking inverted repeats (IRL, IRR, IRRalt1, IRRalt2) are represented by yellow bars and 5 bp direct 
repeat sequences created by duplication of the target sequence during transposition are given (TGAAA, 
TATCT or TATAA). In the primary insertion site, a single 2,855 bp transposon carrying blaOXA-181 has 
inserted at TGAAA (position 1152428..1155282) within MS6671_10430. This transposon, similar to 
Tn2013 previously described in K. pneumoniae Kp331, is flanked by 14-bp inverted repeat sequences, 
namely IRL and IRRalt1. IRRalt2 lies 23 bp downstream of IRRalt1 within the MS6671_10430 sequence. 
Mobilisation of the ISEcp1-blaOXA-181 transposon using IRRalt2 instead of IRRalt1 has resulted in a 37 bp 
fragment of MS6671_10430 (indicated by a small red rectangle) being packaged at the 3’ end of the other 
two ISEcp1-blaOXA-181 transposons inserted at TATCT and TATAA (position 126108..128999 and position 
3345804..3348695, respectively). Grey shading indicates regions of homology (100% nucleotide sequence 
identity) between sequences.
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MS6671, indicating hydrolytic activity of OXA-181 towards these carbapenems and a possible blaOXA-181 
copy number effect (Table  1). Notably, doripenem resistance was higher than previously reported18. 
The ompK36 variant encoded by MS6671 has previously been associated with increased resistance to 
doripenem and doripenem-colistin13, and may contribute to the elevated MIC for doripenem observed 
in MS6671. Porin deficient E. coli expressing OXA-48-like beta-lactamases have also been shown to have 
elevated MICs towards carbapenems18.
Inactivation of mgrB has recently been associated with resistance to colistin, and appears to be the 
most common mechanism for polymyxin resistance in K. pneumoniae19,20. Specifically, disruption of 
mgrB results in over expression of the phoPQ signaling system and of the pmrHFIJKLM operon which 
controls modification of LPS, the target of polymyxin antibiotics36. Insertional inactivation of mgrB with 
IS5-like or IS1 elements has been previously reported21,37, however, the present study is the first to show 
colistin resistance caused by insertion of a carbapenem resistance element itself. While we cannot rule 
out the possibility that this mechanism may have occurred in other colistin-resistant K. pneumoniae 
carrying ISEcp1-blaOXA-18138, the generation of a complete genome sequence of MS6671 provides une-
quivocal evidence for this novel insertion event.
We also found a fourth ISEcp1 element encoding an ESBL (CTX-M-15), which was inserted within 
the outer membrane porin gene ompK35. Disruption of ompK35 reduces the permeability of the outer 
membrane and mutants lacking this porin have increased resistance to quinolones, tetracyclines, 
beta-lactams and chloramphenicol39. Pan-aminoglycoside resistance was mediated by the rRNA methyl-
transferase RmtF, which was encoded on both chromosomal and plasmid copies of a class 1 integron. We 
did not have access to investigational antibiotics, such as plazomicin, eravacycline, ceftazidime/avibactam 
or ceftolozane/tazobactam, to assess their potency against MS6671.
MS6671 was defined by multi-locus sequence typing (MLST) as being ST147. K. pneumoniae ST147 
was first described in Hungary in 200840. Subsequently, it has been frequently associated with carbapenem 
resistance, with ST147 producing KPC well described in Greece and Italy41,42. For example, epidemics of 
VIM-producing carbapenem resistant K. pneumoniae ST14743, and KPC-2-producing carbapenem resist-
ant K. pneumoniae44,45 have been reported in Greece. Notably, ST147 isolates carrying both blaVIM and 
blaKPC-2 genes were identified41,46. Carbapenem resistant ST147 carrying the blaNDM-1 gene have been iso-
lated in Iraq, Switzerland, Canada and the United Kingdom47–49. In MS6671, carbapenem resistance was 
most likely mediated by the beta-lactamase OXA-181, possibly in combination with permeability defects 
as has been reported previously in other strains18,31. ST147 K. pneumoniae producing OXA-181 have 
been previously reported from the Indian sub-continent18,31,50. Clearly, in addition to the KPC-producing, 
carbapenem-resistant K. pneumoniae ST258 clone51, ST147 also represents a clone of K. pneumoniae with 
a potential for global significance.
Fortunately, in six months there have been no further isolates with this resistance phenotype at the 
index patient’s hospital. However, the occurrence of this strain in the Arabian Gulf is of great significance. 
OXA-48-like-producing K. pneumoniae are frequent in this region52. It is unknown if this strain origi-
nated in the index patient, in another patient at the same hospital or was imported from another hospital, 
perhaps in another country. There are a large number of expatriates in the Gulf region, and travel to the 
Indian sub-continent, Europe and the United States is frequent53. The potential for international transfer 
of multidrug-resistant bacteria54,55 emphasizes the need for global surveillance efforts as one part of a 
strategy to control antibiotic resistance3.
In summary, we have provided the first report of a pandrug-resistant isolate of CRE using 
high-resolution genome data. The CDC has denoted CRE as an urgent threat. The emergence of this 
highly resistant strain, in a clone that has proven capable of causing outbreaks, raises this threat level 
even higher.
Methods
Antibiotic Resistance Phenotypic Testing. The K. pneumoniae isolate (hereafter referred to as 
MS6671) was sent to a reference laboratory (University of Queensland, Centre for Clinical Research) 
where confirmatory susceptibility testing was performed in order to determine the minimal inhibitory 
concentrations of all antibiotics used by the Centers for Disease Control and Prevention (CDC) and 
European Centre for Disease Prevention and Control (ECDC) in defining a pandrug-resistant isolate6. 
Susceptibility of most tested antibiotics was determined using Etests and following the breakpoints of the 
European Committee for Antibiotic Susceptibility Testing (EUCAST)56, except for cefazolin, cefoxitin, 
cefotetan, tetracycline, doxycycline, and minocycline which were determined using the breakpoints of 
the Clinical and Laboratory Standards Institute (CLSI)57. The minimum inhibitory concentration of colis-
tin (sulfate, Sigma-Aldrich) was determined by broth microdilution in cation-adjusted Mueller-Hinton 
broth (Oxoid).
Genome sequencing. Pacific Biosciences (PacBio) RS II Single-Molecule Real Time (SMRT) 
sequencing of K. pneumoniae MS6671 was performed using ~4 μ g of the genomic DNA sheared using 
g-TUBETM (Covaris®) into fragments size targeted at 10 kb. Purification of the sheared DNA was 
then carried out using 0.45-fold volume of washed Agencourt AMPure XP magnetic beads (Beckman 
Coulter Inc.). SMRTbell template libraries were subsequently prepared using the commercial Template 
Preparation Kit from Pacific Biosciences Inc. that involved steps of DNA end repair, adapters ligation 
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followed by exonuclease digestion of incompletely ligated products. Next, 0.83 nM of the libraries were 
then annealed with sequencing primers followed by binding to 50 nM of P4 DNA polymerase, as pro-
vided in the Template Binding Kit from Pacific Biosciences Inc. For enhanced loading efficiency, 15 pM 
of the bound complexes were immobilized into Magbeads (Pacific Biosciences Inc.) prior to loading into 
the sequencing zero-mode waveguides (ZMWs). Duration for the sequence collection was set at 180 min-
utes with stage start option. Reads with length that were less than 50 bp were filtered off upon acquisition 
of the sequencing data and minimum polymerase read quality was set at 0.75.
Genome assembly. De novo genome assembly of PacBio SMRT reads from the K. pneumoniae 
MS6671 genome was performed using the hierarchical genome assembly process (HGAP)58 from the 
PacBio SMRT analysis software suit (version 2.2.0), with default parameters and a seed read length cut-off 
of 5 kb. Following assembly, all contigs were screened for duplicate sequences at their 3′ and 5′ ends. 
Overlapping sequences were manually trimmed and joined based on sequence similarity. Individual con-
tigs with duplicate sequences on their 5′ and 3′ ends were manually trimmed and circularised. Following 
circularisation the chromosome and plasmid sequences were polished using quiver58 whereby the raw 
reads were mapped back to the chromosome and plasmid sequences to validate the assembly and resolve 
any remaining sequence errors. Non-circularised chromosomal and plasmid contigs were closed using 
primers designed on their 5′ and 3′ ends. The amplified PCR products were sequenced by the Australian 
Genome Research Facility and their sequences were manually integrated into the assembly.
Genome annotation. Gene calling and automatic functional annotation of the complete MS6671 
chromosome and plasmids was performed using Prokka (Prokka: Prokaryotic Genome Annotation System 
- http://vicbioinformatics.com/) identifying 5,054 putative coding regions on the chromosome with an 
additional 644 putative coding regions distributed amongst the 5 plasmids and linear plasmid prophage. 
The complete annotated genome sequence has been deposited at the European Nucleotide Archive 
(Bioproject: PRJEB7538, Accessions: LN824133-LN824139).
Identification of antibiotic resistance genes. Initial identification of antimicrobial resistance genes 
from the complete PacBio assembly was performed using ResFinder (version 2.0)59. Additional screening 
for antimicrobial resistance genes was performed by comparison (BLASTp; sequence identity > = 40%; 
E-value < = 0.0001) of all predicted coding regions against the Antibiotic Resistance Genes Database 
(ARDB)60 and the Comprehensive Antimicrobial Resistance Database (CARD)61. Antimicrobial resist-
ance genes were then subject to manual inspection to improve their functional annotation, correct start 
sites and identify point mutations, which may contribute to a resistant phenotype. Finally, resistance gene 
loci were screened for known insertion sequences and integrons by comparison against the ISFinder 
database62 and Integrall63, respectively.
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Abstract
The increasing emergence and spread of antimicrobial resistance (AMR) is a serious public health issue. Increasing the awareness
of the general public about appropriate antibiotic use is a key factor for combating this issue. Several public media campaigns
worldwide have been launched; however, such campaigns can be costly and the outcomes are variable and difficult to assess.
Social media platforms, including Twitter, Facebook, and YouTube, are now frequently utilized to address health-related issues.
In many geographical locations, such as the countries of the Gulf Cooperation Council (GCC) States (Saudi Arabia, United Arab
Emirates, Kuwait, Oman, Qatar, and Bahrain), these platforms are becoming increasingly popular. The socioeconomic status of
the GCC states and their reliable communication and networking infrastructure has allowed the penetration and scalability of
these platforms in the region. This might explain why the Saudi Ministry of Health is using social media platforms alongside
various other media platforms in a large-scale public awareness campaign to educate at-risk communities about the recently
emerged Middle East respiratory syndrome coronavirus (MERS-CoV). This paper discusses the potential for using social media
tools as cost-efficient and mass education platforms to raise awareness of appropriate antibiotic use in the general public and in
the medical communities of the Arabian Peninsula.
(J Med Internet Res 2015;17(10):e233)   doi:10.2196/jmir.3891
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Introduction
Antibiotic resistance has become a severe public health threat
worldwide, including in the Gulf Cooperation Council (GCC)
states [1]. Hence, various initiatives across the globe have been
launched to combat this issue. In 2011, the World Health
Organization (WHO) themed its annual day to address this issue
with the slogan “No action today, no cure tomorrow” and listed
the actions to be undertaken. These actions included providing
education to achieve effective antibiotic use [2]. Antibiotic
misuse, such as demanding unneeded antibiotics, purchasing
antibiotics over-the-counter without a prescription, and not
completing a course of antibiotics, is associated with the
emergence and selection of antibiotic-resistant bacteria [3].
Nosocomial infections caused by antibiotic-resistant pathogens
are significantly associated with an increased length of hospital
stay and increased cost [4].
European surveys have shown that the general public still
misunderstands the function and correct use of antibiotics [5,6].
On many occasions, the WHO has highlighted the importance
of involving the general public alongside health care
professionals for combating the emergence of antimicrobial
resistance (AMR) [7,8]. To alleviate the public’s lack of
cognizance about AMR, various countries in Europe [7,9], as
well as the United States [10] and other countries, have initiated
public campaigns to raise awareness about the appropriate use
of antibiotics.
Considering Saudi Arabia and other Gulf countries, various
studies have addressed the issue of antibiotic misuse in hospital
settings and the easy over-the-counter access to prescription
antibiotics. For example, antibiotic use in intensive care units
(ICUs) in Saudi Arabia has been found to be 10 times greater
than that in the United States and some European countries
[1,11-13]. This issue also extends to the wider GCC community.
A Saudi study found that 77.6% of pharmacies dispensed
antibiotics without a prescription primarily to treat scenarios
consistent with viral infections [14], whereas 68.4% of
antibiotics from Abu Dhabi pharmacies were sold
over-the-counter [15], suggesting lack of antibiotics knowledge
[16].
These examples of antibiotics misuse and others suggest the
urgent need for a public campaign in Saudi Arabia and beyond
to provide greater education on the proper use of antibiotics
along with the concept of reserving antibiotics for use only
when they are truly needed. In April 2015, the GCC Center for
Infection Control released the multilevel GCC Strategic Plan
for Combating Antimicrobial Resistance, which sets the
framework for the regional and national plans [17]. One of the
5 strategic roadmaps addressed is the importance of preserving
and restricting the available antimicrobial agents for human use.
Interventional methods include educating antibiotic prescribers,
patients, and the general public on the importance of appropriate
antimicrobials use and basic infection prevention and control
(eg, immunization and hygiene) [17].
Social media platforms are being widely used for health
promotion advocates and to endorse traditional awareness
campaigns. They have unique characteristics for sharing open
access information, providing a platform for dynamic
conversations with communities and social groups, and keeping
users connected with their topics of interest [18]. They have
been used to raise awareness for obesity, diabetes [19], and
adolescent dating violence [20]. As an outreach effort, the
European Antibiotic Awareness Day released a toolkit to advise
on how to engage in social media activities promoting prudent
antibiotic use [18]. Information provided in the toolkit relates
to European countries and may not fully apply to the GCC states.
In this paper, we discuss the planning, setup, and potential
effectiveness of developing a mass education campaign via
social media platforms to raise general public and medical
awareness of appropriate antibiotic usage in the GCC states.
The Influence of Educational Campaigns on Antibiotic
Use and Antibiotic Resistance
Before initiating an educational media campaign, it is important
to review the effectiveness of previous initiatives that were
developed and launched in other parts of the world to raise
awareness and provide guidance on responsible antibiotic use
(Table 1).
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Table 1. Summary of selected antibiotic awareness campaigns worldwide.
Reduction rateTarget audienceMethod usedDurationSite (country)Name
36% reduction in outpatient
antibiotic use per 1000 inhab-
itants per day during winter
season
Belgian communityMultimedia campaigns, nation-
al campaigns, publication of
clinical practice guidelines,
support for the establishment
of antibiotic management teams
(AMTs)
Launched in
1999-present
BelgiumBelgian Antibiotic Poli-
cy Coordinating Com-
mittee (BAPCOC ) es-
tablishment [21]
26.5% reduction of antibiot-
ic prescriptions per 100 in-
habitants during winter sea-
son over a 5-year period
General public and
health care profession-
als
Mass media campaigns, one-
on-one physician education
sessions
2001-2007All 22 regions
across France
“Les antibiotiques c’est
pas automatique” (“An-
tibiotics are not automat-
ic”); part of the national
campaign “Keep antibi-
otics working” [22]
Unknown as yetAll AustraliansFacebook, Twitter, online
pledging
2012-presentAustraliaAntibiotics Awareness
Week [23]
4.3% reduction in defined
daily doses of prescribed
antibiotics in intervention
group
General publicBrochures, posters, local media
advertisements, and visual aids
November 2011-
Februrary 2012
Emilia-Ro-
magna region
(Northern Italy)
Local low-cost informa-
tion campaign [9]
No improvement observed
in postsurvey of public’s
understanding
General publicPosters displayed in magazines
and newspapers
2008England and
Scotland
English public antibiot-
ic campaigns [7]
Not assessedJunior and senior
school students
Website-based gamesLaunched in
2006-present
European coun-
tries and Saudi
Arabia
e-Bug [24]
Data from Belgium and France have also revealed a reduction
in the misuse of antibiotics after educational interventions. A
decrease of 26.5% in antibiotic prescriptions was observed in
France between 2002 and 2007 compared with the
preintervention period (2000-2002), with the largest reduction
observed in children [22]. A 36% reduction in antibiotic
prescriptions was also observed in Belgium from 1999-2000 to
2006-2007 [21]. Both countries also reported a decrease in the
incidence of infection with invasive penicillin- and
macrolide-resistant Streptococcus pneumoniae. It was noted
that the decrease in Belgium occurred before the wider use of
the pneumococcal conjugate vaccine (PCV7), indicating that
the vaccine did not contribute to this initial reduction in the
incidence of infection with invasive penicillin-resistant
pneumococci [5,6]. These data suggest the effectiveness of
antibiotic awareness media campaigns in decreasing the use of
antibiotics and hence in reducing the impact of antibiotic
resistance.
Recently, Formoso et al [9] reported the effectiveness of a
low-cost media campaign on antibiotic use in an Italian province
that lasted for 5 months during the cold season. The intervention
materials included visual aids, such as posters, brochures, and
advertisements, which were used in the local media. The key
messages of the campaign were codesigned by a physician
practicing in the intervention area. Antibiotic prescriptions were
significantly reduced by 4.3% in the intervention area compared
with the control area. However, the general population’s
knowledge and attitudes about antibiotic resistance were not
changed by the campaign [9].
In 2008, antibiotic awareness campaigns were carried out in
England and Scotland by broadcasting key messages in
advertising published in magazines and newspapers.
Unfortunately, the campaign did not show any positive effects
in either England or Scotland. No improvement was observed
in the general public’s understanding of antibiotic misuse to
treat coughs and colds despite the fact that in 2009 more public
respondents agreed that “resistance to antibiotics is a problem
in British hospitals” than in 2008 [7]. In fact, this is not the only
documented failure of antibiotic awareness campaigns. Huttner
et al [5] reviewed 22 campaigns launched in high-income
countries between 1990 and 2007. At least 3 of these campaigns
failed and the effect of 3 others is unknown because of a lack
of follow-up assessment on antibiotic use [5].
The e-Bug project is an example of an innovative approach to
raise awareness about microbes and infection prevention. The
aim of the e-Bug project is to disseminate educational materials
about microbes (both beneficial and pathogenic) to junior and
senior school students across Europe. The project relies on
website-based gaming and entertainment-based lessons [24].
The e-Bug project now has partners in 26 different European
countries, as well as Saudi Arabia, providing educational
materials in different European languages and in Arabic [25].
On May 2015, the e-Bug website had a total of 17,391 visitors
and the Saudi Arabian site had 76 visitors in total [26]. The
impact of the e-Bug project is not clear because no evaluation
of its implementation and impact on behavioral changes in
targeted groups was ever performed [24].
Various factors have been suggested to be necessary to achieve
success in antibiotic awareness campaigns. These include
carefully designing key messages that are clear and simple,
targeting both general public individuals and clinicians, and
using television and radio [6,7]. Moreover, motivating
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physicians to be involved in communicating with patients about
the appropriate use of antibiotics and antibiotic resistance is
also important [7]. Physicians’ participation in developing
campaign messages and communicating with the general public
might significantly improve the chances of success. Early
engagement can also have an impact on the sense of ownership
of the campaign and facilitate physicians’ consistent support
[27]. This may indirectly influence physicians, focusing their
attention on antibiotic prescribing and providing greater patient
education.
Variable Sociological Factors
Awareness messages that display local surveillance data or
amount of antibiotics locally misused may be important. Sharing
with the general public the real-life experiences of individuals
who have been infected with “superbugs” could be useful and
may help the audience identify with those affected. Sharing
real-life medical experience has been shown to be a useful
communication platform from which to clarify public
health-related stories, such as acne and cancer [28,29].
Considering these factors when designing awareness campaigns
about antibiotics may help make an impact in GCC
communities. Based on the Health Belief Model, perceived
susceptibility (ie, you are at risk of getting infected) can be used
to raise awareness [30,31]. However, delivering known
messages to the target audience might result in a loss of interest
and later disengagement. Educational interventions would be
more successful if local contexts and barriers are adequately
analyzed and addressed.
Replicating campaign strategies that have been initiated in
different global regions outside the GCC region might not result
in an effective outcome. It is crucially important to study the
cultural factors and antibiotic distribution infrastructure in the
GCC before thinking about the awareness messages. For
example, the United States’ Get Smart campaign [32] highly
recommends that parents do not demand antibiotics for their
children from the treating physician. We do not believe that this
message line will be as effective as it might be in the United
States because antibiotics can be purchased without a
prescription from community pharmacies; therefore, a doctor’s
refusal might not make a difference. Approximately 37% of the
total population of the GCC states consists of nonnational
expatriates [33]; hence, it is important to consider cultural
differences and not to neglect this segment when setting up a
public awareness campaign. For example, the Saudi Ministry
of Health has generated educational materials in multiple
languages to fulfill this requirement [34].
Community pharmacies have a significant role in dispensing
antibiotics in GCC communities. For example, 24.4% of 1645
recently surveyed antibiotic transactions in community
pharmacies in Abu Dhabi were carried out without a
prescription, including amoxicillin-clavulanic acid for sore
throats and ceftriaxone for sexually transmitted infections [35].
The illegal practice of selling antibiotics over-the-counter,
without a prescription, did not favor expatriates over citizens
in the surveyed pharmacies in Abu Dhabi [15].
The self-prescription of antibiotics is another sociological factor
that must be considered when designing antibiotic awareness
campaigns in the GCC states [36,37]. This factor is strongly
associated with the availability of antibiotics over-the-counter.
Before creating content to be used for awareness campaigns, it
is necessary to conduct formative research to assess the public’s
existing knowledge of antibiotics resistance, understand the
motivations for inappropriate antibiotics use, and learn about
the social and cultural backgrounds for the targeted population.
That will subsequently help to develop tailored key messages
that can potentially encourage behavioral change [30]. Knowing
these critical elements has lead to the success of many awareness
campaigns, such as The Magic Glasses video to prevent
soil-transmitted helminthes in China [31,38]. On the other hand,
content produced for social media-based campaigns can be
unrelated to the campaign’s target. For example, it was found
that the majority of Movember campaign-related tweets did not
associate with prostatic and testicular cancer awareness [39],
and the majority of tweets produced during breast cancer
awareness week did not promote any specific preventive
behaviors [40]. Despite the importance of developing related
content, research into the correlation between social media-based
awareness campaigns and behavior change is minimal because
it is a new avenue in public health awareness [41].
Social media platforms can also contain contradictory health
messages with potentially negative impact. Because social media
platforms give users the freedom to publish their content, some
of that content can contain medically misleading information,
as found in YouTube videos promoting anorexia [42].
Funding
Funding is an important factor that may significantly affect a
campaign’s functionality and outcome. A systematic review of
more than 20 international campaigns aimed at raising awareness
of antibiotic use showed that these campaigns sourced their
funding from different sectors, including the pharmaceutical
industry [6]. The funding spent by pharmaceutical companies
on promoting and marketing antibiotics is massive. For example,
in 1998, it was estimated that pharmaceutical companies in the
United States spent approximately US $1.6 billion to promote
antibiotics [43]. On the other hand, media campaigns that
encourage the prudent use of antibiotics are not widely supported
[6]. Government funding is important. Because antibiotic
awareness campaigns might translate into wiser use of
antibiotics and potentially lead to a reduced selection of resistant
bacteria, public funding should be offered to support awareness
campaigns.
The cost of running a traditional mass media campaign to
promote prudent antibiotic use in the community can be very
expensive. For example, developing and conducting the French
antibiotic awareness campaign carried out from 2002 to 2007
cost approximately €500 million over a 6-year period [44],
whereas the Belgian campaign cost considerably less at
approximately €400,000 per year [21]. The “Get Smart
Colorado” campaign, which took place for 4 months in 2002,
reported a cost of US $88,500 to purchase advertising space
that included bus tails, bus stop posters, interior bus signs, and
national public radio spots [10]. Similarly, the recent Italian
campaign in 2013 cost approximately US $60,800 for purchasing
media spots on television and radio, and in newspapers.
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Approximately the same cost was spent to develop and print
written visual aid materials, such as posters [9].
Considering social media platforms are free, establishing a
social media-based campaign may be far cheaper than traditional
media-based campaigns. However, in order to maintain
continuous cyber presence and followers scalability, social
media managers are usually hired [45], which can be an
additional cost burden on social media-based campaigns. The
key advantage of social media is the possibility to measure and
track impressions and responses to online posts. These data can
be used to guide social media campaigns to improve marketing
strategy. However, platforms available to analyze big data
generated from social media can be costly and may require
technical expertise.
Time
Repeating the educational intervention over a long period of
time is essential for the awareness success of mass media
campaigns. Repetition over a long period of time has been
demonstrated for causes such as smoking cessation and has
helped achieve effectiveness [46]. The vast majority of antibiotic
awareness campaigns launched in high-income countries
between 1990 and 2007 were conducted over a period of more
than 1 year [6]. Other campaigns, such as European Antibiotic
Awareness Day (on November 18 each year) [47], are seasonal
and have a long-term sustainable plan. However, the “Get Smart
Colorado” campaign, which lasted for only 4 months,
successfully showed a 3.8% net reduction in antibiotic
dispensing at retail pharmacies as well as an 8.8% net decrease
in managed care-associated antibiotic dispensing [10].
The ease of using social media, along with the indirect
community contribution via “share” and “retweet” features,
might provide long-term exposure and awareness messages to
the wider general public. However, it is important to consider
the temporal effect of social media feeds due to their short
lifespan. It was found that the half-life of a tweet is
approximately 24 minutes, whereas the half-life of Facebook
posts is approximately 90 minutes [48]. A hashtag is a keyword
preceded by a hash sign (#) that is used to identify and
categorize messages on a specific topic, which can give the
topic a longer lifespan in social media [49,50]. Keeping the
audience engaged and interested in the topic is another important
consideration. This might be achieved by ensuring that the key
messages and materials are not overrepeated throughout the
campaign’s duration. Updating campaign materials with new
and relevant data might keep the audience more engaged and
keen to receive updated educational materials. Lastly, the time
chosen to post the social media message can be critical for the
lifespan of social media posts [51].
The Value of Social Media Platforms to Communities
in the Gulf Cooperation Council States
The total number of users of the social networking website
Facebook in the Arab world (22 countries) had grown to
54,552,875 by the end of May 2013; 33.4% of users are female
and 68% are younger than 30 years [52]. Facebook users in the
GCC states represent approximately 22% (12 million) of the
total Facebook users in the Arab world [52] (Table 2).
Table 2. The use of Internet and social media platforms in the GCC states.
Twitter users (million),d n (%)Facebook users (million),c n (%)
Internet users (million),
n (%)bPopulation (million)aCountry
1.9 (6.7)6.4 (22.5)13.0 (45.8)28.4Saudi Arabia
0.4 (4.8)3.4 (41.7)5.7 (71.0)8.3United Arab Emirates
0.2 (7.3)0.8 (26.8)2.0 (63.2)3.1Kuwait
0.1 (5.6)0.3 (25.1)1.0 (80.0)1.2Bahrain
0.1 (4.4)0.6 (34.4)1.7 (99.9)1.7Qatar
0.04 (1.2)0.5 (16.4)2.1 (63.6)3.3Oman
a Population figures obtained from [53].
b Internet user figures obtained from [54].
c Facebook user figures obtained from [52].
d Twitter user figures obtained from [55].
For the microblogging website Twitter, the number of active
users in the Arab world reached 3,766,160 individuals as of
March 2013, with an estimated 10,832,000 tweets per day. Saudi
Arabia has the highest number of active Twitter users in the
Arab world, with 1.9 million individuals, which is approximately
50% of the total Twitter users in the Arab region. Approximately
47% and 11% of the total tweets in the Arab world are generated
from Saudi Arabia and United Arab Emirates, respectively.
The video-sharing website YouTube is also a popular media
platform in the GCC, particularly in Saudi Arabia. As an update
to research conducted by Forbes Middle East, we present data
from selected local GCC talk shows on YouTube (Table 3). It
is clear that these shows attract many viewers, although some
shows from Saudi Arabia receive the most attention. This
audience would make these shows an excellent platform for
delivering awareness messages to a larger number of viewers.
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Table 3. The popularity of selected YouTube-based shows in the GCC states.
Average views per
episodeaTotal viewsaSubscribersaEpisodesaLaunch dateOriginName of show
3,137,875197,686,1281,714,69963Feb 2011Saudi ArabiaEyshElly
1,365,02961,462,338810,11945Sep 2010Saudi Arabia3al6ayer
2,208,72372,887,865649,46533Sep 2010Saudi Arabia
847750,8642156Jul 2013OmanEndam Cinema
74,781972,165668613Jun 2012United Arab
Emirates
Balalee6
190,963954,81510,1335May 2012United Arab
Emirates
149,5598,076,19367,47754Jan 2012Kuwaitshenoya3nitv
NA2,973,37617,7591May 2014Saudi ArabiaHow to Prevent from
Corona
a The figures were obtained from YouTube channels on November 15, 2013.
Examples of Saudi Public Health Awareness Messages
Delivered Through Social Media Platforms
Owing to its high profile and popularity among Internet users
in the GCC region, YouTube has often been used in Saudi
Arabia as a platform to deliver public health–related awareness
messages and campaigns (Table 4). We have noticed 2 different
models for delivering health-related topics on YouTube in Saudi
Arabia. One model was noticed in many campaigns that used
comedy talk shows with large audience as a platform to deliver
the awareness messages. With the help of other social media
platforms, such as Facebook and Twitter, these messages have
traveled far and wide, attracting a large number of viewers. For
example, a Saudi-based comedy show named “Fe2aFala”
released an episode about acquired immune deficiency syndrome
(AIDS) and this episode attracted over 1 million viewers.
Table 4. Health messages delivered through Saudi YouTube-based shows.a
Channel subscribersNumber of viewersAwareness aboutTypeShow/channel name
14,8213,288,241bPhosphine gasSpecial episodePhosphine
807,5612,583,534Health promotionSpecial showLumink
296,5631,489,802Breast cancerSpecial episodeTelfaz11
351,9071,139,948AIDSSpecial episodeFe2aFala
29,3731,292,959Dental careEntire showSen_tube
51,7461,097,713Obesity and well-beingEntire show3almezan
81,725455,485DiabetesSpecial episodeHotcoldshow
93788,703Health promotionEntire showMedScoope
a The figures were obtained by accessing the YouTube channels on the March 4, 2014.
b This number of views was achieved within only 3 days of uploading the video on YouTube.
Another model is to use YouTube as a channel similar to
traditional mass media to distribute health awareness messages.
For example, in June 2014, the Saudi Arabia Ministry of Health
launched an engaging public awareness campaign using
YouTube, Twitter, Facebook, educational posters, and health
guideline updates to educate the general public and medical
communities on the emergence of, and health precautions needed
for, MERS-CoV [34]. In this example, social media platforms
may have been used to create online presence to endorse
awareness messages delivered locally on traditional media. It
must be noted that the incidence rate of MERS-CoV has
declined [56] with the multi-faceted intervention, which social
media has been a part of.
Publishing awareness content on social media might allow
international distribution and an indefinite exposure period.
However, in order to potentiate the effectiveness of a YouTube
video, additional advertising strategies must take place. Table
4 summarizes some of the campaigns that have used YouTube
shows to deliver public health awareness in Saudi Arabia and
have attracted a high number of views.
Our Pilot Experience
Many health care facilities and organizations have started using
Twitter as a teaching tool; for example, “tweeting” about
specific health problems has been used by major organizations
such as the Centers for Disease Control and Prevention (CDC),
WHO, the National Cancer Institute (NCI), and the National
Institutes of Health (NIH). “Tweets” go out from a sender and
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are simultaneously received by all members of a group of
“followers,” providing a fast, open, and easy way to deliver a
particular focused message.
We used Twitter in our online Arabic-language pilot campaign
focusing on superbugs using a hashtag. We delivered short
tweets and links to various articles and videos related to
superbugs. We also translated multiple non-Arabic research
articles and news for our more than 34,000 followers, who were
primarily from Saudi Arabia and the surrounding areas. This
medium gave us the ability to have a real-time conversation by
answering their questions and concerns about the topic. To track
our efforts, we regularly reviewed the number of followers,
updates, retweets, and “mentions” in Twitter. Many evaluation
metrics for Twitter can be collected. We evaluated our Twitter
pilot study by analyzing the influence of some of our tweets.
We kept track of how many of our “followers” published
updates including “retweets” or “at replies” over time. A simple
analysis of 147 selected tweets with the Arabic superbug hashtag
resulted in approximately 4100 retweets between July and
November 2013. This information does not tell us which of the
tweets encouraged followers to go on to read the full article or
watch the video, but it does give us useful information on
general interest levels.
We created a whiteboard animation with a voiceover video [57]
that discussed the importance of antibiotics, how superbugs are
created, and the spread of superbugs in the GCC. We also
discussed possible factors that could contribute to the emergence
and spread of superbugs in addition to advice on how to control
superbugs as reviewed previously [1].
Interestingly, the number of retweets that we received from our
superbugs hashtag correlated with the number of YouTube
views that we recorded for our video. The video viewing pattern
as determined by YouTube was as expected: there were a large
number of views soon after the video was posted and released
on Twitter, and there were fewer views from 3 weeks later until
the present day. We observed 2 large peaks in viewing rates
within the first 2 weeks of the video being released. We believe
the first one was due to our successful Twitter activities. We
are unclear about what caused the second and largest jump in
YouTube views. It is possible that the video was picked up by
another group and spread on Twitter again (Figure 1).
We also observed sporadic smaller peaks in YouTube views
from 3 weeks onward. These numbers suggest that the video
was still drawing attention and being shared, most likely on
social media, even months after being posted.
Our viewer retention rate was consistent with what YouTube
estimates to be the average retention rate for videos of a similar
length—approximately half of the video. This rate suggests that
the length of our video—5.5 minutes—is adequate to capture
the viewers’ attention.
Subsequently, we created an infographic video uploaded on
YouTube [58] that combined a selection of our tweets with
visual and audio enhancement. The tweet that featured the video
received 152 retweets and 130 favorites, and the video was
viewed more than 3000 times in only 2 weeks (Figure 2).
The content generated for our pilot campaign was primarily
dependent on our existing knowledge of antibiotic misuse in
Saudi Arabia and neighboring states as previously reviewed
[1,14-16,35-37]. We acknowledge the limitations of our pilot
campaign resulting from the lack of formative research, its
Arabic content, and reliance on social media. In order to achieve
prospective behavioral change, it is important to understand the
motivation for antibiotic misuse in the general public. Future
research should conduct a thorough survey, interviews, and
observations to cover the diverse population of the GCC states.
This will help us design relevant key messages to be used in
future awareness campaigns. The diverse ethnic groups and
socioeconomic status of people in the Gulf States should also
be considered in future campaigns because more languages and
media platforms might need to be used. Relying solely on a
social media platform in an awareness campaign might overlook
the large population of migrant workers in the GCC who might
not have access to social media platforms.
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Figure 1. YouTube views over a period of 84 days for the whiteboard animated and voiceover video about superbugs and proper antibiotics use.
Figure 2. YouTube views over a period of 20 days for the infographic video.
Conclusion
Reducing the suboptimal use of antibiotics among the general
public and medical community through awareness activities is
an important element in national plans to combat rising AMR.
However, it is important to create awareness content that is
related to the target audience and based on formative research.
Social media platforms seem to be a valuable platform for
delivering awareness messages. Owing to social media
popularity, awareness messages could reach a large number of
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users and the reach can be tracked. Through our pilot experience
we have successfully distributed antibiotics awareness messages
through Twitter and YouTube to our target audience in the Gulf
counties and Saudi Arabia. The use of social media can also
enhance awareness campaigns delivered in traditional media
channels. However, it is important to consider the cultural
demographic diversity, which could limit the reach of awareness
massages, such as the high population of immigrant workers in
the GCC who might not have access to these emerging social
media platforms. Social media–based messages can also have
short life span, which might limit the effect and reach of key
awareness messages. Measuring the impact of the social
media–based awareness campaigns on the general public’s
understanding and behavioral change is a challenge and needs
further research.
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Genetic Contexts of blaNDM-1 in Patients Carrying Multiple NDM-
Producing Strains
Alexander M. Wailan,a Anna L. Sartor,b Hosam M. Zowawi,a,c,d John D. Perry,e David L. Paterson,a,f,g,h Hanna E. Sidjabata
The University of Queensland, UQ Centre for Clinical Research, Herston, Queensland, Australiaa; Health Protection Branch, Department of Health, Queensland
Government, Brisbane, Queensland, Australiab; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabiac; WHO Collaborating Centre for Infection
Prevention and Control and GCC Center for Infection Control, Riyadh, Saudi Arabiad; Department of Microbiology, Freeman Hospital, Newcastle upon Tyne, United
Kingdome; Australian Infectious Diseases Research Centre, Brisbane, Australiaf; Infectious Diseases Unit, Royal Brisbane and Women’s Hospital, Brisbane, Australiag;
Pathology Queensland, Brisbane, Australiah
The carbapenem resistance determinant blaNDM-1 has been found in various Gram-negative bacteria and upon different plasmid
replicon types (Inc). Here, we present four patients within two hospitals in Pakistan harboring between two and four NDM-1-
producing Gram-negative bacilli of different species coresident in their stool samples. We characterize the blaNDM-1 genetic con-
texts of these 11 NDM-1-producing Gram-negative bacilli in addition to other antimicrobial resistance mechanisms, plasmid
replicon profiles, and sequence types (STs) in order to understand the underlying acquisition mechanisms of carbapenem resis-
tance within these bacteria. Two common plasmid types (IncN2 and IncA/C) were identified to carry blaNDM-1 among the six
different bacterial species isolated from the four patients. Two of these strains were novel Citrobacter freundii ST 20 and ST 21.
The same IncN2-type blaNDM-1 genetic context was found in all four patients and within four different species. The IncA/C-type
blaNDM-1 genetic context was found in two different species and in two of the four patients. Combining genetic context character-
ization with other molecular epidemiology methods, we were able to establish the molecular epidemiological links between ge-
netically unrelated bacterial species by linking their acquisition of an IncN2 or IncA/C plasmid carrying blaNDM-1 for carbap-
enem resistance. By combining plasmid characterization and in-depth genetic context assessment, this analysis highlights the
importance of plasmids in antimicrobial resistance. It also provides a novel approach for investigating the underlying mecha-
nisms of blaNDM-1-related spread between bacterial species and genera via plasmids.
Infectious pathogens have the ability to be transmitted from oneperson to another. Antimicrobial resistance in certain instances
has been observed to follow this paradigm of transmission; specif-
ically, bacterial species have been described as transmitting anti-
microbial resistance determinants. A well-known example of a
successful international clone is the Escherichia coli sequence type
(ST) 131 transmitting blaCTX-M-15 (1, 2). However, numerous re-
ports in the last few years provide evidence that plasmids are a
major factor in the transmission of antimicrobial resistance (3, 4).
Since the first report (5), blaNDM has been reported to be har-
bored by a diverse range of bacterial species, among which the
most frequent are within the Acinetobacter genus and Enterobac-
teriaceae family (6, 7). Furthermore, blaNDM has also been identi-
fied to reside upon different plasmid replicon types (Inc) among
the Enterobacteriaceae family, including IncA/C (8), IncF types
(9), IncL/M (10), IncN (11), IncX (12), and IncH (13). In addi-
tion, the genetic structure or context in which blaNDM resides var-
ies between different plasmid types and evenwithin the same plas-
mid type (14). The blaNDM-1 genetic contexts observed with
Enterobacteriaceae plasmids frequently involve various mecha-
nisms of gene acquisition, including different ISCR elements (15),
class one integrons (16), flanking insertion (IS) elements (15), and
singleton IS elements present in close proximity (8, 10). In con-
trast, blaNDM genetic contexts within Acinetobacter spp. have been
reported with less variation since blaNDM can be commonly found
within the 10,099-bp transposon known as Tn125, composed of
two flanking ISAba125 sequences (7, 17–19).
The Indian subcontinent is recognized as a major reservoir for
blaNDM acquisition and has been suggested as the geographical
origin of blaNDM (6, 20). In a previous study from our group, 66
NDM-1-producing Gram-negative isolates from stool samples of
patients in two Pakistani hospitals were reported (20). Among
patients harboring these isolates, four patients were found to carry
multiple NDM-1 producers of different species. Sartor and col-
leagues also determined that the species within each patient were
characterized by different plasmid replicon type profiles (20). This
warranted further investigation in order to elucidate the underly-
ing nature of blaNDM-1 acquisition by different species when the
bacterial hosts have different plasmid replicon profiles. The aim of
this study was to further characterize the different NDM-produc-
ing bacterial species coexisting in multiple patients through
whole-genome sequencing, noting their resistance mechanisms
and sequence types (STs) with a further focus on characterizing
the blaNDM-1 genetic contexts.
(Part of this work was presented as a poster at the 25th Euro-
pean Congress of Clinical Microbiology and Infectious Diseases,
Copenhagen, Denmark, 25 to 28 April 2015).
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MATERIALS AND METHODS
Bacterial isolates. Eleven clinical isolates were acquired in 2010 from stool
samples from four different patients in two hospitals in Rawalpindi, Pakistan
(21). In the study conducted byPerry and colleagues (21), one patient carried
four species, threepatients had three species, andfivepatients had two species
of NDM-1 producers (data not shown). Isolates were selected based on the
number of isolates present in the patients and the diversity of their plasmid
typeprofiles,whichwasdeterminedbyPCR-based replicon typing (PBRT)of
Enterobacteriaceae isolates as previously described (20, 22). The strains
identified from each patient are as follows (Table 1): patient 1, Enterobac-
ter cloacae Pn2, Acinetobacter baumannii Pn3, Klebsiella pneumoniae Pn4,
andCitrobacter freundiiPn5; patient 2,Pseudocitrobacter faecalisPn13 and
Escherichia coli Pn14; patient 3, P. faecalis Pn27 and E. coli Pn28; patient 4,
E. coli Pn66, C. freundii Pn67, and E. cloacae Pn68.
Plasmid transfer experiments through conjugation. Plasmids carry-
ing blaNDM-1 from clinical strains were transferred by conjugation to con-
firm their transferability and plasmid replicon type. For conjugation ex-
periments, the 11 clinical isolates (donor strains) were verified to be
susceptible to sodium azide via agar dilution. Donor strains and sodium
azide-resistant E. coli J53 recipients were grown in LB broth at 200 rpm to
logarithmic phase (23). The conjugation mixture consisted of donor and
recipient strains in a 1:1 ratio that were plated onto MacConkey agar and
then incubated at 37°C overnight (24). The conjugation mixture of ap-
proximately 20 l of confluent growth on the plate was then harvested
into 1ml of saline and serially diluted in saline to 108. This serial dilution
method was performed to obtain single colonies of both donors and
transconjugants between the serial dilutions of 104 and 106. One hun-
dred microliters of each dilution was then inoculated onto MacConkey
agar supplemented with meropenem (0.1 g/ml) and sodium azide (100
g/ml) or with sodium azide only (100 g/ml) and onto a control plate
without additives; plates were incubated at 37°C for 24 h. Successful
transconjugants were confirmed phenotypically and through PCR for
blaNDM-1. PBRT was performed on transconjugants to identify the plas-
mid replicon type carrying blaNDM-1 (22).
Sequencing and bioinformatics. Paired-end libraries of whole
genomic DNA of all 11 clinical isolates were prepared and sequenced by
the Illumina MiSeq platform (Illumina, San Diego, CA, USA). All se-
quences were de novo assembled using the CLC Genomic Workbench,
version 7.5 (CLC Bio, Aarhus, Denmark). pNDM-BJ01 (GenBank acces-
sion number JQ001791) (17) was manually annotated and used as a ref-
erence for Tn125 structure annotation. Sequences from the GenBank da-
tabase and IS Finder (https://www-is.biotoul.fr/) were used to identify
and characterize genes flanking the Tn125 region. The CLC Genomic
Workbench was used for a BLAST search (http://blast.ncbi.nlm.nih.gov
/Blast.cgi) and to analyze and manually annotate the genetic context of
blaNDM-1 according to the aforementioned reference sequences. Contigs
containing blaNDM-1 were named as follows: patient 1, pPN2-ECL-
NDM-1 (E. cloacae Pn2), PN3-AB-NDM-1 (A. baumannii Pn3), pPN4-
KP-NDM-1 (K. pneumoniae Pn4), and PN5-CF-NDM-1 (C. freundii
Pn5); patient 2, pPN13-PCF-NDM-1 (P. faecalis Pn13) and pPN14-EC-
NDM-1 (E. coli Pn14); patient 3, pPN27-PCF-NDM-1 (P. faecalis Pn27)
and PN28-EC-NDM-1 (E. coli Pn28); patient 4, pPN66-EC-NDM-1 (E.
coli Pn66), pPN67-CF-NDM-1 (C. freundii Pn67), and pPN68-ECL-
NDM-1 (E. cloacae Pn68).
Contigs of each clinical strain were submitted to the ResFinder, ver-
sion 2.1 (25) (https://cge.cbs.dtu.dk/services/ResFinder/), and Plasmid-
Finder, version 1.1 (26), databases (available at the Center of Genomic
Epidemiology website [http://www.genomicepidemiology.org]) to char-
acterize their resistance mechanism genes and plasmid Inc types.
Sequence typing via an MLST scheme. Each clinical isolate was sub-
mitted to the MLST, version 1.7, database (27) (https://cge.cbs.dtu.dk
/services/MLST/) for sequence typing via respective multilocus sequence
TABLE 1 Strains and their respective sequence types, antimicrobial resistance profiles, and plasmid replicon typing resultsd
a PBRT was performed on transconjugants carrying the plasmid harboring blaNDM.
b This enzyme is responsible for aminoglycoside and quinolone resistance.
c Novel Citrobacter freundii sequence types determined by MLST.
d Shaded boxes indicate the replicon types and genes present in each strain as determined by PlasmidFinder and ResFinder. N/A, not applicable (no positive plasmid replicon typing
results for Acinetobacter species and no MLST scheme for P. faecalis).
Wailan et al.
7406 aac.asm.org December 2015 Volume 59 Number 12Antimicrobial Agents and Chemotherapy
 o
n
 O
ctober 21, 2016 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
typing (MLST) schemes, except for P. faecalis strains Pn13 and Pn27 as no
MLST schemes were available (28). Both C. freundii strain Pn5 and strain
Pn65 were identified as novel sequence types and subsequently submitted
to the C. freundii MLST website (http://pubmlst.org/cfreundii/) (29) for
assignment of new sequence types.
Nucleotide sequence accession numbers. Each nucleotide sequence
was deposited in the GenBank database under the following accession
number: pPN2-ECL-NDM-1, KP770024; PN3-AB-NDM-1, KP770025;
pPN4-KP-NDM-1, KP770033; PN5-CF-NDM-1, KP770032; pPN13-
PCF-NDM-1, KP770031; pPN14-EC-NDM-1, KP770030; pPN27-PCF-
NDM-1, KP770029; PN28-EC-NDM-1, KP770023; pPN66-EC-NDM-1,
KP770028; pPN67-CF-NDM-1, KP770027; and pPN68-ECL-NDM-1,
KP770026.
RESULTS AND DISCUSSION
The molecular and in silico analysis results of each NDM-1-pro-
ducing strain are summarized in Table 1. These results also
include for each strain the clinically significant antimicrobial
resistance determinants found within each strain, ST type, and
replicon type (Inc) of the plasmid carrying blaNDM-1 (deter-
mined via PBRT of successful transconjugants). In silico anal-
ysis of each contig with blaNDM-1 initially identified a truncated
Tn125 structure harboring blaNDM-1 (Tn125). The sizes of
Tn125 structures were variable (Fig. 1). Different genes and
IS elements were identified flanking the Tn125 structures
(Fig. 1). The combination of the different Tn125 structure
sizes and flanking contexts identified four distinct blaNDM-1
genetic contexts.
The most common blaNDM-1 genetic context, 5=-aacA1
blaOXA-10 Tn125-3= (identified in 5 of 11 strains and in all four
patients), contained a 2,341-bpTn125 structurewith aacA1 con-
ferring aminoglycoside resistance and a truncated narrow-spec-
trum -lactamase, blaOXA-10, upstream and was determined to be
on IncN2-type plasmids (expect in Pn28 andPn67). This blaNDM-1
genetic context was found within three different bacterial species,
K. pneumoniae Pn4 (pPN4-KP-NDM-1), P. faecalis Pn13 and
Pn27 (pPN13-PCF-NDM-1 and pPN27-PCF-NDM-1, respec-
tively), E. coli Pn14 and Pn28 (pPN14-EC-NDM-1 and PN28-EC-
NDM-1, respectively), and C. freundii Pn67 (pPN67-CF-NDM-
1), and is similar to anE. coli isolate from Japan (direct submission
under GenBank accession number AB769140) and to two IncN3
plasmids, pLK75 (GenBank accession numberKJ440076) ofE. coli
and pLK78 (GenBank accession number KJ440075) of K. pneu-
moniae isolated from Taiwan (11). Transmission of blaNDM-1 may
have occurred via conjugation of an IncN2 plasmid with this ge-
netic context, as suggested by our successful conjugation experi-
ments involving strains carrying IncN2 plasmids. These conjuga-
tion events would subsequently result in the different bacterial
FIG 1 Schematic representation of all blaNDM genetic contexts described within this study and the reference sequence pNDM-BJ01 (GenBank accession number
JQ001791). blaNDM genetic contexts and their GenBank accession numbers are as follows: Pn2, pPN2-ECL-NDM-1 (KP770024); Pn3, PN3-AB-NDM-1
(KP770025); Pn4, pPN4-KP-NDM-1 (KP770033); Pn5, PN5-CF-NDM-1 (KP770032); Pn13, pPN13-PCF-NDM-1 (KP770031); Pn14, pPN14-EC-
NDM-1 (KP770030); Pn27, pPN27-PCF-NDM-1 (KP770029); Pn28, PN28-EC-NDM-1 (KP770023); Pn66, pPN66-EC-NDM-1 (KP770028); Pn67, pPN67-
CF-NDM-1 (KP770027); and Pn68, pPN68-ECL-NDM-1 (KP770026). , truncated gene. Insertion sequence (IS) elements are represented as block arrows.
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species producing NDM-1 within three of the four patients. The
IncN2 blaNDM-1 genetic context was also found inC. freundii Pn67
in the fourth patient; however, it was identified on an IncFIIY-type
plasmid. This genetic context was also identified in E. coli Pn28
and believed to be located on the chromosome or on a noncon-
jugative plasmid as conjugation experiments were unsuccessful
after multiple attempts. The blaNDM-1 genetic contexts in Pn28
and Pn67 are highly similar to those of the IncN2 plasmids of
our study as well as to those in the literature; however, they
were not located on IncN2 plasmids. It may be speculated the
“IncN-like” blaNDM-1 genetic contexts of Pn28 and Pn67 may
have diverged from the IncN2 plasmids of our study through
such events as homologous recombination (30). Alternatively,
Pn28 and Pn67 could have been the source from which the
IncN2 plasmids acquired the blaNDM-1 genetic context prior to
horizontal gene transfer among the different species. Further
investigation, including full plasmid construction, will be re-
quired to clarify the nature of these two isolates and the poten-
tial for blaNDM-1 cassette transfer between the plasmid back-
bones IncN2 and IncFIIY.
Another blaNDM-1 genetic context observed, found in 3 of the
11 isolates, involved a longer 6,332-bp Tn125 structure. In con-
trast to the aforementioned IncN2 Tn125 structure, this longer
Tn125 structure was flanked by an ISKpn14 element and trun-
cated ISEcp1 upstream and by a truncated type IV secretion pro-
tein, rhs, downstream (Fig. 1). This IncA/C blaNDM-1 genetic con-
textwas determined to be on IncA/C-type plasmids andwas found
in two patients, patient 1, carrying E. cloacae strain Pn2 (pPN2-
ECL-NDM-1), and patient 4, carrying E. coli strain Pn66 (pPN66-
EC-NDM-1) and E. cloacae strain Pn68 (pPN68-ECL-NDM-1).
Similar to the aforementioned IncN2 blaNDM-1 genetic contexts,
the IncA/C blaNDM-1 genetic context was also observed within two
different species within the same patient (patient 4). Further, it is
very similar to the most frequently reported IncA/C blaNDM-1 ge-
netic context of theEnterobacteriaceae family (8, 14, 31). The com-
bination of IncA/C blaNDM-1 genetic context identification (Fig.
1), the previously reported clonal spread of E. cloacae and E. coli
within these hospitals, and the identification of IncA/C plasmids
as the most prevalent plasmid types (20) might suggest the
contribution of this specific IncA/C plasmid to the carriage and
transmission of carbapenem resistance among Enterobacteria-
ceae within this clinical setting.
Out of the 11 isolates, two unique genetic contexts for blaNDM-1
were found in PN3-AB-NDM-1 (A. baumannii Pn3) and PN5-
CF-NDM-1 (C. freundii Pn5) in patient 1. PN3-AB-NDM-1 car-
ried a context composed of the longest Tn125 structure (7,962
bp), which is very similar to the Tn125 lengths frequently de-
scribed within the Acinetobacter genus; i.e., it was composed of a
full Tn125 structure extending from the left-hand ISAba125 ele-
ment to the right-hand ISAba125 (7, 18, 32, 33). PN5-CF-NDM-1
contained a 7,288-bp Tn125 structure flanked by two IS3000
sequences (truncated left-hand ISAba125 to truncated ISCR27)
with plasmid backbone elements in close proximity, such as traA.
This context has not been previously reported. Both blaNDM-1 ge-
netic contexts, PN3-AB-NDM-1 and PN5-CF-NDM-1, may po-
tentially be located on a nonconjugative plasmid or on the chro-
mosome, as suggested by unsuccessful transfers in conjugation
experiments. Of note, both PN3-AB-NDM-1 and PN5-CF-
NDM-1were found in patient 1, who carried four differentNDM-
1-producing species, i.e., E. cloacae,A. baumannii,K. pneumoniae,
and C. freundii, each with a different blaNDM-1 genetic context
(Fig. 1).
The characterized blaNDM-1 genetic contexts of 11 clinical iso-
lates retrospectively may suggest interspecies transmission of an-
timicrobial resistance at an in vivo level via plasmids. This has been
previously described with blaKPC (34). Initial characterization of
our isolates identified different plasmid replicon profiles with
multiple species within the same patient. Genetic characterization
in combination with other molecular typing methods has de-
scribed, clarified, and provided an insight into the spread and
acquisition of blaNDM-1. Apart from the nonconjugative blaNDM-1
found in Pn3, Pn5, and Pn28 and the single IncFIIY plasmid in
Pn67, the remaining strains have become carbapenem resistant by
acquiring IncN2- and IncA/C-type plasmids with the specific
aforementioned blaNDM-1 genetic contexts.
The prevalence of highly similar blaNDM-1 genetic contexts
within different species and among different patients highlights
the possible role plasmids are able to provide in interspecies trans-
mission of carbapenem resistance. We suggest that genetic char-
acterization of plasmids with respect to blaNDM-1 could be consid-
ered a tool similar to the multilocus sequencing typing (MLST)
approach, which utilizes the typing of conserved regions within
the genome for comparison, to investigate the clonal epidemiol-
ogy of antibiotic-resistant bacteria (1, 35, 36). By considering ge-
netic context characterization in combination with standard
molecular methods (bacterial species identification, resistance
mechanism profiling, and clonality via MLST) during epidemio-
logical studies, sophisticated epidemiological links between pa-
tients and genetically unrelated bacterial species can be clarified in
the case of blaNDM-1 and potentially other plasmid-mediated an-
timicrobial resistance determinants that have genetic context vari-
ation, such as blaCTX-M-type (37, 38) or blaCMY-type (39). Such in-
vestigation will assist in clarifying whether within a specific
geographical region and facility antimicrobial resistance acquisi-
tion by species has occurred via a particular plasmidwith a specific
genetic context.
Here, we have characterized the genetic nature in which
blaNDM-1 resides in different NDM-1-producing bacterial species
coexisting in multiple patients and identified IncA/C and IncN2
plasmids as the platform providing carbapenem resistance to oth-
erwise diverse and unrelated species of Enterobacteriaceae within
the clinical setting of two hospitals in Pakistan. The combination
of in-depth genetic plasmid characterization and epidemiological
molecular investigation methods presented here not only high-
lights the ability of plasmids to transmit andprovide antimicrobial
resistance determinants to various bacterial species and genera but
also provides a novel approach for investigating the underlying
mechanisms of blaNDM-1-related spread associated with hospital-
ized patients.
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Rapid diagnostics
Acb complexAcinetobacter baumannii, one of themore clinically relevant species in theAcinetobacter genus iswell known to be
multi-drug resistant and associated with bacteremia, urinary tract infection, pneumonia, wound infection and
meningitis. However, it cannot be differentiated from closely related species such as Acinetobacter calcoaceticus,
Acinetobacter pittii and Acinetobacter nosocomialis bymost phenotypic tests and can only be differentiated by spe-
ciﬁc, time consuming genotypic tests with very limited use in clinical microbiological laboratories. As a result,
these species are grouped into the A. calcoaceticus–A. baumannii (Acb) complex. Herein we investigated the
mass spectra of 73 Acinetobacter spp., representing ten different species, using an AB SCIEX 5800 MALDI-TOF
MS to differentiate members of the Acinetobacter genus, including the species of the Acb complex. RpoB gene se-
quencing, 16S rRNA sequencing, and gyrBmultiplex PCR were also evaluated as orthogonal methods to identify
the organisms used in this study. We found that whilst 16S rRNA and rpoB gene sequencing could not differen-
tiate A. pittii or A. calcoaceticus, they can be differentiated using gyrBmultiplex PCR and MALDI-TOF MS. All ten
Acinetobacter species investigated could be differentiated by their MALDI-TOF mass spectra.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Acinetobacter baumannii is an opportunistic, aerobic, Gram-negative
nosocomial pathogen that has become one of the six most important
multi-drug resistant microorganisms worldwide (Antunes et al.,
2014).A. baumannii is commonly known to cause difﬁcult to treat pneu-
monia, bacteremia, urinary tract infection, wound infection andmenin-
gitis (Maragakis and Perl, 2008).
Accurate identiﬁcation of A. baumannii and its closely related species
Acinetobacter pittii, Acinetobacter nosocomialis and Acinetobacter
calcoaceticus is important as each of these species may display different
characteristics in regard to antimicrobial susceptibilities, pathogenicity
and clinical outcomes (Chuang et al., 2011; Sedo et al., 2013). The envi-
ronmental strain A. calcoaceticus has not been reported to cause infec-
tion in humans whilst the other organisms are all of clinical
signiﬁcance (Peleg et al., 2008, 2012). A recent paper has described in-
creased severity and mortality in bacteraemia patients infected with
A. baumannii compared with those infected with A. pittii andA. nosocomialis, emphasising the need for accurate differentiation
(Fitzpatrick et al., 2015).
However, these four species which together make up the
A. calcoaceticus–A. baumannii (Acb) complex are indistinguishable by
phenotypic based tests (Peleg et al., 2008; Wang et al., 2013; Lee et al.,
2014).
Molecularmethods such as 16S rRNA and rpoB gene sequencing and
have shown to be useful in differentiatingmembers of the Acinetobacter
genus (La Scola et al., 2006; Zarrilli et al., 2009;Wang et al., 2014). How-
ever, neither method is sufﬁcient to differentiate species such as A. pittii
and A. calcoaceticus (Higgins et al., 2010), and other molecular methods
such as PCR ampliﬁcation of intrinsic resistance genes or gyrB are used.
However, these methods are mainly applied in research settings and
have very limited use in clinical laboratories (La Scola et al., 2006;
Higgins et al., 2010; Kamolvit et al., 2014).
Matrix assisted laser desorption ionisation — time of ﬂight mass
spectrometry (MALDI-TOFMS) has been shown to be a rapid and highly
discriminatory method for the identiﬁcation of bacteria (Kliem, 2010;
Welker et al., 2011; Sedo et al., 2013). MALDI-TOF instruments that
are commonly used in clinical settings for bacterial identiﬁcation rely
on the use of proprietary identiﬁcation software and spectral databases
(Martiny et al., 2012).
129B.E.W. Toh et al. / Journal of Microbiological Methods 118 (2015) 128–132In this study, we evaluated the use of a research-use-only (RUO)
5800 MALDI-TOF MS (AB SCIEX, Concord, ON, Canada) to differentiate
and identify various species in the Acb complex, as well as other
Acinetobacter spp. using only the standard instrument software and
freely available open-source software for the acquisition, processing
and interpretation of spectra.2. Materials and methods
2.1. Bacterial isolates and reference strains
The strains investigated in our study included thirty two multilocus
sequence typed (MLST typed) A. baumannii isolates, six Acinetobacter
reference strains and thirty ﬁve additional Acinetobacter isolates as de-
scribed below:
The MLST typed A. baumannii isolates included sixteen isolates of
sequence type (ST)110, four isolates of ST92 and three isolates of
ST109 (Huber et al., 2014). In addition to this, four isolates of from
the Arabian peninsula were added to the study, including one isolate
from Saudi Arabia of the ST195 and one of ST436, respectively, plus
one isolate of ST208 from Kuwait and one of ST229 from Qatar
(Zowawi et al., 2015).
Two additional isolates of ST208 were of Japanese origin, and one
isolate of ST208 was from Thailand, and two Singaporean strains were
of ST491 (Kamolvit et al., unpublished data). The isolates from Japan,
Thailand and Singapore were collected between 2008 and 2010, and
the MLST typing was performed in silico. The Kenyan strains and the
strains from the Arabian peninsula were collected and MLST typed as
previously described (Huber et al., 2014; Zowawi et al., 2015). MLST
typing has been performed according to the Oxford scheme for all iso-
lates (http://pubmlst.org/abaumannii/).
The following reference strains and previously published isolates
and were added to the study; A. baumannii ATCC 19606,
A. calcoaceticus ATCC 14987, Acinetobacter lwofﬁi ATCC 15309 and
ATCC 17986, Acinetobacter johnsonii ATCC 17909, Acinetobacter junii
ATCC 17908, Acinetobacter baylyi (n = 1), A. calcoaceticus (n = 1),
A. pittii (n= 1) (Peleg et al., 2012) and A. nosocomialis (n= 2) (Peleg
et al., 2012; Carruthers et al., 2013).
Various additional Acinetobacter spp. from Kenya (n = 4, provided
by the AGA KHAN University hospital in Nairobi, Kenya and collected
between 2010–2011), Japan (n= 12, provided by the Toho University
in Tokyo, Japan and collected in 2010), Australia (n = 2, collected at
the Royal Brisbane and Women's hospital in Brisbane, Australia in
2004 and 2006 respectively), Thailand (n = 7, provided by the Siriaj
Hospital in Bangkok), Singapore (n=5, collected in 2008 and provided
by the National University of Singapore). All isolates were grown on
Mueller Hinton agar and incubated for 24 h in a 37 °C incubator, and
identiﬁcation and conﬁrmation of species was performed as described
in chapter 2.2.2.2. 16S rRNA identiﬁcation
All Acinetobacter spp. isolates were initially identiﬁed by the se-
quencing of the 16S rRNA gene as previously described (Misbah et al.,
2005). Sequencing was performed by Macrogen Inc., Seoul, Korea, and
sequences were blasted on NCBI using the megablast function against
the 16S ribosomal RNA sequences database with maximum target se-
quences being set at 100. If 16S rRNA sequencingwas unable to identify
an isolate using the highest percentage identity, score and an E-value of
0 resulting in a sequence that matches two species with identical
lengths, rpoB gene sequencing of zones 1 and 2was performed as previ-
ously described (La Scola et al., 2006). A previously described gyrBmul-
tiplex PCR (Higgins et al., 2010)was used to differentiate A. calcoaceticus
and A. pittii.2.3. MALDI-TOF MS
MALDI-TOF MS analyses were conducted on a 5800 TOF/TOF set in
linear positive mode running the TOF/TOF Series Explorer acquisition
software (AB SCIEX, Framingham, Massachusetts) at a laser frequency
of 100 Hz with a set mass range of 3000 to 20,000 Da. A continuous
stage motion set in a random pattern at 600 μm/s was used for
sampling.
An in-house sinapinic acid matrix consisting of 10 mg of sinapinic
acid (N99.0% for MALDI-MS, Fluka 85,429) in 500 μL acetonitrile,
475 μL distilled water and 25 μL 80% triﬂuoroacetic acid (TFA, LC-MS
grade, Fluka 40967) was adapted from a previously published protocol
(Freiwald and Sauer, 2009). Calibration was performed using calibra-
tion mixture 2 (AB SCIEX, Framingham, Massachusetts) which
contained Angiotensin I, ACTH (1–17 clip), ACTH (18–39 clip), ACTH
(7–38 clip) and insulin (bovine) to ensure mass accuracy within 5 ppm.
2.4. Acquisition of mass spectra
A small amount of bacteria (approximately 106–108 cfu) was trans-
ferred from a 24 h culture by spreading a thin layer onto a sample spot
on an Opti-TOF 384 MALDI plate insert (AB SCIEX, Framingham,Massa-
chusetts) and overlaid with 1 μL of sinapinic acid matrix. Each isolate
was spotted in quadruplicate and each replicate scanned once. Laser in-
tensity was set at 4322 units and at a pulse rate of 100 Hzwith a total of
1000 spectra accumulated for each sample. Amass range ofm/z 3000 to
m/z 20,000 and a continuous stage motion set in a random pattern at
600 μm/s was used for sampling. The TOF/TOF Series Explorer acquisi-
tion software (AB SCIEX, Framingham, Massachusetts) was used to ac-
quire mass spectra.
2.5. Processing of spectra
Mass spectra ﬁles were non-manipulatively converted from t2d ﬁles
to mzXML ﬁles using a t2d converter (http://www.pepchem.org) and
processed using mMass version 5.50 (Strohalm et al., 2008) (http://
www.mmass.org/). Processing of raw spectra was conducted in
mMass 5.5 (Martin Strolham) with a peak picking algorithm that used
baseline correction, Savitzky-Golay smoothing and a signal to noise
ratio of 3. Replicates of the same isolates were averaged to form a con-
sensus spectrum.
3. Results
3.1. Bacterial identiﬁcation
Using 16S rRNA identiﬁcation, we conﬁrmed the following
Acinetobacter spp. in our collection; A. baumannii (n = 37),
A. nosocomialis (n= 15), A. junii (n= 3), A. lwofﬁi (n= 2), A. johnsonii
(n= 1), A. baylyi (n= 1), Acinetobacter soli (n= 1) and Acinetobacter
bereziniae (n= 1).
Using rpoB gene sequencing and gyrBmultiplex PCR we determined
the remaining fourteen strains to be A. pittii (n = 12) and
A. calcoaceticus (n= 2). The results are as summarised in Table 1.
3.2. MALDI-TOF MS based characterisation
All ten Acinetobacter species investigated in our study had sufﬁcient
differences in their mass spectra to be characterised and differentiated
using MALDI-TOF MS. In all of the A. baumannii strains investigated
(n = 35) we observed the presence of a characteristic, high intensity
mass of m/z 5743.05, as well as two other speciﬁc masses of m/z
8583.00 and m/z 8715.00 that could be used to distinguish
A. baumannii from other Acinetobacter spp. (Fig. 1). Additionally, all
the species that were not part of the Acb complex could also be
characterised and differentiated (Summarised in Table 1).
Table 1
Acinetobacter spp. investigated in this study with the methods that were used to identify each species and their indicative MALDI peak masses.
Bacterial
species
Methods of species conﬁrmation Indicative MALDI peak
masses (m/z)
A. baumannii (n= 35) 16S rRNA gene sequencing 5743.05, 8583.00 and 8715.00
A. nosocomialis (n= 15) 16S rRNA gene sequencing 8134.00, 8542.00 and 8315.00 or 8356.00 or 8481.00
A. pittii (n= 12) 16S rRNA gene sequencing, rpoB gene sequencing and gyrBmultiplex PCR 5743.05 or 5780.03, 8620.00, 8822.00
A. junii (n= 3) 16S rRNA gene sequencing 10,849.00
A. calcoaceticus (n= 2) 16S rRNA gene sequencing, rpoB gene sequencing and gyrBmultiplex PCR 5829.00
A. lwofﬁi (n= 2) 16S rRNA gene sequencing 7613.00, 7662.00, 9101.00 and 9219.00
A. johnsonii (n= 1) 16S rRNA gene sequencing 4309.00 and 6720.00
A. baylyi (n= 1) 16S rRNA gene sequencing 5669.00
A. soli (n= 1) 16S rRNA gene sequencing 5519.00
A. bereziniae (n= 1) 16S rRNA gene sequencing 8018.00 and 9247.00
130 B.E.W. Toh et al. / Journal of Microbiological Methods 118 (2015) 128–132Nine of the twelve A. pittii isolates studied had a representative high
intensity mass of m/z 5780.03 and two other speciﬁc masses of m/z
8620.00 and m/z 8822.00. In addition, three of the twelve isolates
were also characterised by amass atm/z 5743.05, with similar intensity
to that of the one in A. baumannii. However, the mass at m/z 5780.03
was absent (Fig. 1).
In A. nosocomialiswe observed a representative mass atm/z 8134.00
in all isolates, and anothermass atm/z 8542.00 in fourteen of ﬁfteen iso-
lates (Fig. 2). In A. calcoaceticus, we observed a representative promi-
nent peak at m/z 5829.00 that occurred in both isolates of this species
(Fig. 2).4. Discussion
Retrospective studies found that A. baumannii was associated with
higher mortality rates, greater antimicrobial resistance and different
clinical characteristics than the ones of A. nosocomialis and A. pittii
(Chuang et al., 2011; Lee et al., 2011; Yang et al., 2013). This raises theFig. 1. (A)Mass range ofm/z 3000–7000 of A. baumannii and A. pittii. The red arrow indicates th
isolates have themass ofm/z 5743.05, normally indicative ofA. baumannii. However, none of the
A. pittii. The red arrows indicate the masses ofm/z 8583.00 andm/z 8715.00 that are representa
which are representative of A. pittii.importance of being able to differentiate the organisms within the Acb
complex to allow for treatment to be optimised for speciﬁc organisms.
A. calcoaceticus–A. baumannii complex organisms are hard to differ-
entiate because of high phenotypic similarities (Gerner-Smidt et al.,
1991). Molecular methods such as 16S rDNA and rpoB sequencing as
well as gyrB PCR ampliﬁcation are possible methods to discriminate be-
tween these strains. We observed that 16S rRNA sequencing or rpoB
gene sequencing were not sufﬁcient to differentiate A. pittii and
A. calcoaceticus, and that the identiﬁcation of these two organisms re-
quired gyrBmultiplex PCR. However, in our investigation these species
showed MALDI-TOF mass spectra that are clearly distinct from each
other.
MALDI is a soft desorption ionisation method which may result in
the formation of ions without signiﬁcantly breaking chemical bonds,
which is particularly useful in protein analysis.MALDI instruments com-
monly used for bacterial identiﬁcation use licensed software packages
that are incompatible with instruments of other brands. Such instru-
ments are usually single TOF mass analysers that do not allow for efﬁ-
cient structure and sequence investigation of analytes. The ABSciexemass ofm/z 5743.05 and the blue arrow indicates themass ofm/z 5780.03. Three A. pittii
A. pittii isolates have bothmasses. (B)Mass Range ofm/z 7000–15,000 ofA. baumannii and
tive of A. baumannii. The blue arrows indicate themasses ofm/z 8620.00 andm/z 8822.00
Fig. 2. (A)Mass range ofm/z 3000–7000 of A. nosocomialis andA. calcoaceticus. The red arrow indicates themass ofm/z 5829.00which is indicative ofA. nosocomialis. (B)Mass Range ofm/z
7000–15,000 of A. nosocomialis and A. calcoaceticus. The blue arrows indicate the masses m/z 8134.00, m/z 8542.00, m/z 8315.00 or m/z 8356.00 or m/z 8481.00 that are indicative of
A. nosocomialis.
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overcome the limitations of a single TOF mass analyser by linking two
TOF mass analysers in series, making it a much more powerful tool in
protein research (Ng et al., 2014). However, due to the lack of a data-
base, bacterial identiﬁcation is not readily performed with this
instrument.
The use of freeware to augment the abilities of RUO instruments
such as the 5800 TOF/TOF greatly increase the functionality and avail-
ability of these instruments for bacterial identiﬁcation. The ability to dif-
ferentiate species without using automated systemsmay be a step back
from the automated systems that the VITEK-MS and the Biotyper offer,
but it validates the ability of MALDI-TOF instruments to visualise spec-
tral differences for greater discrimination between closely related
species.
As we have seen in our study, MALDI-TOF was able to differentiate
closely related species such as A. pittii and A. calcoaceticus. It appears
that MALDI-TOF may also differentiate various Acinetobacter spp. from
each other, as well as organisms that fall within the Acb complex. Auto-
mated processes would be required if this method is to be used as part
of a diagnostic procedure.
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Antimicrobial resistance in Saudi Arabia
An urgent call for an immediate action
Hosam M. Zowawi, MClinSc (ClinMicro) (Hons), PhD. 
ABSTRACT
 ةيضقك  تاداضملل  ةمواقلما  تابوركيلما  ىلع  ءوضلا  طيلست  ديازَت
 ىلجتي  .ملاعلا  ءاحنأ  عيمج  يف  رشبلا  ةحصلو  ناويلحا  ةحصل  ةحلُم
 ةيويلحا تاداضلما مواقت يتلا ايريتكبلا يف حضاو لكشب عوضولما اذه
 يف جلاعلل ةلباق ريغ ىودعب ءىبني امم .ريخأ رايخك اهمادختسا دنع
 تابوركيلما ةحفاكلم تايجيتارتسا ةيلودلا تلااكولا تحرتقأ .لبقتسلما
 ةيبرعلا  ةكلملما  يف  تايدحتلا  نم  ديدعلا  كانه  .تاداضملل  ةمواقلما
 ةيودلأل ةمواقلما ايريتكبلا راشتناو روهظ زفتح نأ نكيم يتلا ةيدوعسلا
 تاعاطق  نم  دوهجم لذب  نم  دبلا تايدحتلا  هذه  ةهجاولم  .ةددعتلما
 ةمواقلما  تابوركيلما  روهظو  راشتنا  ىلع  حاجنب  ةرطيسلل  ةددعتم
 روهظ  عبتتل  ةلاّعفلا  ةبقارلما  تاءارجلإا  نمضتت  نأ  دبلا  .تاداضملل
 ينستح يف ةيولولأا ءاطعإ نم ًاضيأ دبلاو .اهراشتناو تابوركيلما هذه
 نم  .اهراشتنا  نم  دحلل  اهتحفاكمو  ىودعلا  نم  ةياقولا  تاطايتحا
 ريغ ةيويلحا تاداضلما مادختسا نم دحلل يعولا ىوتسم عفر يرورضلا
 ،تايفشتسلما يف ةيويلحا تاداضلما ةرادإ جمارب ىلع يغبنيو ،ةبسانلما
 رمتسلما  مادختسلاا  ميظنت  تايلديصلاو  ،ةيجرالخا  تادايعلاو
.ةيويلحا تاداضملل
Antimicrobial resistance (AMR) is increasingly being 
highlighted as an urgent public and animal health 
issue worldwide. This issue is well demonstrated in 
bacteria that are resistant to last-line antibiotics, 
suggesting a future with untreatable infections. 
International agencies have suggested combating 
strategies against AMR. Saudi Arabia has several 
challenges that can stimulate the emergence and 
spread of multidrug-resistant bacteria. Tackling 
these challenges need efforts from multiple sectors 
to successfully control the spread and emergence of 
AMR in the country. Actions should include active 
surveillance to monitor the emergence and spread of 
AMR. Infection prevention and control precautions 
should also be optimized to limit further spread. 
Raising awareness is essential to limit inappropriate 
antibiotics use, and the antibiotic stewardship 
programs in hospital settings, outpatients, and 
community pharmacies, should regulate the ongoing 
use of antimicrobials.
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Antimicrobial resistance (AMR) in bacteria is emerging and spreading rapidly worldwide. This 
phenomenon is nowadays affecting public and animal 
health dramatically on a global level. The discovery 
of penicillin in the last century provided significant 
advancements in modern medicine, as well as our ability 
to treat commonly encountered infectious diseases, 
one of the biggest killers during the pre-antibiotics 
era. Many of life-saving interventions, such as cancer 
chemotherapy and major surgeries depend on effective 
antimicrobials to succeed.1 Unfortunately however, 
the current dependence on antibiotics - whether to 
treat, prevent, or stimulate food animal growths - 
have exponentially increased this resistance. When 
antibiotics are used, selective pressure is created, and 
possibly forcing the exposed bacteria to mutate or 
acquire pieces of DNA to become antibiotic resistant.2 
The selection pressure resulting from the overwhelming 
use and misuse of antibiotics is exponentially supporting 
the AMR phenomenon.3 Despite this known fact, 
approximately 10 million tons of antibiotics are globally 
used every 10 minutes, which mostly are not related to 
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justified medical use.4 As a result to the global march 
of AMR, common infections, such as urinary-tract 
infections are becoming difficult to treat. This is mainly 
due to bacteria that are resistant to last-line antibiotics,2 
or even pan-drug resistant that are not responding to 
any commercially available antibiotics.5 The multidrug-
resistant (MDR) pathogens are spreading rapidly in 
many parts of the world causing severe medical and 
economic consequences. It is estimated that at least 
every 10 minutes a patient dies in the USA or Europe 
because of fatal infections caused by antibiotic resistant 
bacteria.6 This article gives a brief overview on the 
current situation of AMR in Saudi Arabia and the 
immediate actions needed to tackle this issue.
The emergence and spread of AMR bacteria 
in Saudi Arabia. Current and future challenges. A 
systematic literature review of MDR in Gram-negative 
bacilli (GNB) showed a substantial increase in the rate 
of carbapenem-resistant GNB in Saudi Arabia over the 
last decade in comparison with the rates of the 1990s. It 
also documented the increasing prevalence of extended 
spectrum beta-lactamase (ESBL) producing isolates 
from Saudi Arabia, where some institutes had 29% ESBL 
rates among Escherichia coli (E. coli) and 65% ESBL 
rates among Klebsiella pneumoniae (K. pneumoniae). As 
a result, these increasing rates have been associated with 
many reported outbreaks and mortality that ranged 
between 11-40%.7
Recent region-wide surveillance studies reported that 
most of carbapenem resistant Enterobacteriaceae (CRE) 
from the Gulf Cooperation Council States (GCC) have 
been found to harbor the carbapenemase encoding 
genes blaOXA-48-type, and blaNDM-1.
8 Carbapenem resistant 
Acinetobacter baumannii (A. baumannii) (CRAB) from 
Saudi Arabia have also increased dramatically over the 
years. A recent study from Riyadh9 showed that the 
susceptibilities of A. baumannii to meropenem and 
imipenem in 2006 ranged between 64-81.2%, while 
the susceptibility in 2012 ranged between 8.3-11%. 
Molecular investigation on different CRAB isolates 
obtained from all of the GCC states revealed that large 
number of isolates, from different states, have clustered 
together, suggesting clonality.10
The last-line resource antibiotic currently available 
to tackle many of carbapenem resistant GNB is colistin. 
However, colistin resistant and even pan-drug resistant 
GNB have already been reported. Colistin resistance is 
typically chromosomally mediated and generally not 
transmissible between bacteria. Nevertheless, the recent 
description of plasmid-mediated colistin resistance 
mechanism mcr-1 has enormous implications on the 
lifespan of colistin.11 Plasmid carrying mcr-1 was found 
in many parts of the world among Enterobacteriaceae 
and non-fermentative GNB.11 A recent report 
highlighted the presence of the mcr-1 gene in 4 E. coli 
that were isolated between 2012-2015 from Saudi 
Arabia, Bahrain, and the United Arab Emirates.12 It 
is likely though that mcr-1 carrying GNB are widely 
disseminated in more isolates and between other species 
in the Arabian Peninsula.
Other studies from the GCC region5,13 affirmed 
that the region harbours other rare and novel antibiotic 
resistance mechanisms. For example, PME-1 ESBL 
producing Pseudomonas aeruginosa (P. aeruginosa) from 
Qatar,13 and the pandrug-resistant K. pneumoniae from 
neighboring UAE.5 The latter report provides a very 
significant finding, as this breakthrough should raise 
the global attention to avoid the possible catastrophic 
future of AMR, which can be caused by such an 
untreatable pathogen.
A Saudi national surveillance on Gram-positive 
cocci demonstrated that 32% of Staphylococcus aureus 
(S. aureus) are methicillin-resistant (MRSA), and 33% 
of Streptococcus pneumoniae are resistant penicillin G 
and 26% are resistant to erythromycin.14 A study from 
Riyadh15 demonstrated that S. aureus was colonizing the 
nasal cavity of 40% of the 200 tested healthcare workers. 
Among those S. aureus, 45% were methicillin-resistant 
(MRSA), resulting in total prevalence of 18% health 
workers carrying MRSA. A national survey16 on anti-
tuberculosis drug resistance found that only 1.6% of 
total TB demonstrated MDR phenotype. These figures 
of high prevalence among different bacterial species in 
Saudi Arabia are unfortunately likely to be sustained, if 
not increased to due to several factors.
Local risk factors contributing to the emergence and 
spread of AMR. Several factors are associated to the 
increasing emergence and spread of MDR bacteria in 
Saudi Arabia. It is evident that the unoptimized use of 
antibiotics is a major factor for AMR development. A 
hospital in Riyadh has well demonstrated the overuse 
of antimicrobial agents from 4 adult ICUs in 2010, 
where the highest use was meropenem (33.2 defined 
daily doses [DDD] per 100 bed-days), followed by 
piperacillin-tazobactam (16.0 DDD/100 bed-days). 
On the other hand, the DDD/100 bed-days in 37 ICUs 
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in the United States was 3.75 for carbapenems and 7.08 
for antipseudomonal penicillins.7 Over-the-counter 
antibiotics without prescription in Saudi community 
pharmacies is another issue that is driving the improper 
use of antibiotics. Only one out of 88 pharmacists in 
Eastern province refused to sell antibiotics without a 
prescription, and 77.6% of the pharmacies in Riyadh 
dispensed antibiotics without a prescription.7 To my 
knowledge these are no published evidences from 
Saudi Arabia demonstrating the use of antibiotics as a 
growth promoter. However, several reports, in fact, have 
described the isolation of various MDR GNB from 
food animal specimens.7
Heavy international travel activities are occurring due 
to the large population of expatriates and to pilgrimage 
the holy cities. Travel is a known risk factor for acquiring 
and transmitting infectious diseases, including those 
caused by antibiotic resistant bacteria. A recent study17 
showed that returned travellers from Hajj have acquired 
MDR A. baumannii and NDM producing E. coli during 
the Hajj event. Previous data from 2 major hospitals in 
Makkah showed that ceftazidime resistance is evident in 
24.6% of E. coli, 34.4% of K. pneumoniae, and 52.7% 
of P. aeruginosa. Another report showed that septicemia 
episodes in Makkah are increased by 16.5% during Hajj 
time due to the influx of international patients.7
Another issue that can contribute to the spread 
of AMR is the challenges related to the adherence 
of infection control practices. The hand hygiene 
compliance rate in a hospital in Makkah in 2011 was 
50.3%. The effectiveness of hand hygiene compliance 
was well demonstrated in controlling a nosocomial 
outbreak caused by carbapenem-resistant K. pneumoniae 
in Riyadh.7 Figure 1 illustrates the several factors that 
may contribute to the emergence and spread of AMR.
Immediate actions needed. To limit this alarming 
threat on human health, the World Health Organization 
launched the Global Action Plan on Antimicrobial 
Resistance.18 This plan was signed off by most of 
member states, including Saudi Arabia during the 
Figure 1 - Different factors can stimulate the emergence and spread of 
multidrug-resistant bacteria. 
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World Health Assembly in 2015. The plan consists of 
5 pillars; to improve awareness, stringing knowledge 
through surveillance, reduce the incidence of infection, 
optimize the use of antimicrobial agents, and develop 
the economic case for sustainable investment to support 
the need in all countries in regards to new medicines, 
diagnostic tools, vaccines, and other interventions. To 
have tailored strategies, different countries initiated their 
own national AMR action plans, and the most notable 
similarity between all action plans is the willingness 
to tackle the antimicrobial misuse in both human and 
animal/agricultural sectors.
Raising public, medical, and veterinary awareness of 
AMR is an important element that is urgently needed 
to tackle AMR in Saudi Arabia. Previous research7 
has shown that antibiotics are widely used in the 
community, without prescription, to treat unrelated 
scenarios. Multilevel and nationwide awareness 
campaigns in Saudi Arabia are needed to align with 
the World Antibiotic Awareness Week. The success of 
these campaigns can be dependent on the tailored and 
relevant content and key messages that are designed after 
formative research. The increasing use of social media 
platforms in the country can also help to disseminate 
awareness messages. It is very essential however, to 
consider all segments and socioeconomic groups in the 
Saudi society, as some members might not speak the 
local language, or actively use social media platform.19
Infection prevention and control plays a very 
important role to limit the spread of AMR. Conducting 
educational programs for healthcare workers regarding 
the importance of hand hygiene compliance can 
limit the spread of outbreak stains within hospitals, 
and potentially to the community.7 Hospitals might 
apply screening scheme for high-risk patients prior to 
admission to identify carriers of MDR pathogens and 
to apply isolation or contact precautions in order to 
limit spread.
Active ongoing surveillance on AMR is essential to 
aid the development of tailored treatment guidelines for 
empirical antibiotic therapy, particularly for community-
acquired infections. Developing local surveillance of 
AMR bacteria that are related to nosocomial infections 
can also helps to track emerging resistance to antibiotics 
and to identify outbreaks.7 Hence, microbiology 
laboratories should be well equipped to provide valid 
and reliable identification for pathogen, as well as 
antibiotic susceptibility tastings. As part of their routine 
services, microbiology laboratories should also be able 
to provide up-to-date antibiograms at a hospital level 
and contribute to local surveillance programs. With 
the widely accessible molecular-based techniques and 
Table 1 - Recommendations for actions to stakeholders in the Saudi Arabia to combat antimicrobial resistance.
Recommendations
Antimicrobial stewardship programs
Active guidelines should be implemented to restrict unnecessary use of antibiotics in Saudi hospitals.
Abolition of over-the-counter sales of antimicrobials without prescriptions. 
Regulations and strategies should be used to enforce the ban of antibiotics as growth-promoters in Saudi animal farms and restrict the use of important 
antimicrobials as listed by the World Health Organization - Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGSIR).
Initiating mass educational campaign about antibiotic use
To raise awareness about antibiotic resistance and limit the improper use of antibiotics. 
Cultural differences should be considered when implementing educational campaigns to be delivered to the population of Saudi Arabia.
The highly utilized social media platforms should be used to disseminate messages, but not solely.
Basic infection control precautions (for example, hand hygiene)
Should be emphasized among healthcare workers.
Patients who have been hospitalized internationally need to be screened by the receiving institute for multidrug-resistant organisms.
Infection prevention policy defining at-risk patients and management strategies (for example, empirical treatment, and isolation) should be developed.
Microbiology laboratories
Microbiologists should be updated with local, national, regional and international surveillance to prepare screening and confirmatory testing for emerging 
resistance mechanisms.
Molecular and protein-based identification tools should also be considered to improve diagnosis and to reduce turn-around time. 
Active surveillance
Developing local surveillance of antimicrobial resistant organisms in hospitals, regional and national levels to help suggesting empirical treatments and 
in outbreak tracking. 
Molecular-based techniques and whole genome sequencing should be utilized to give greater insight about the antibiotic resistance mechanisms and clone 
disseminations.
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whole genome sequencing, the use of these technologies 
on AMR can provide a richer insight on the clonal 
disseminations of certain species, and the genotypic 
characterization of antibiotic resistance mechanisms.7 
Surveillance in Saudi Arabia can help contribute to the 
global understanding of the burden of the AMR, which 
is still poorly quantified.2 It was suggested that countries 
should introduce death register records “deaths caused 
by antimicrobial-resistant infection”.6
Last but not least, active antibiotic stewardship 
guidelines should be implemented to restrict the 
irrational use of antibiotics in Saudi Arabia. These 
guidelines should aim to reduce over prescription and 
misprescription of antibiotics in outpatient settings, 
community pharmacies, hospital, and agricultural 
sectors. The WHO and Advisory Group on Integrated 
Surveillance of Antimicrobial Resistance (AGSIR) have 
published an updated list of antimicrobials according 
to their importance in human medicine.20 This list can 
immediately be used to control the use of medically 
important antimicrobials from food animal and 
agricultural settings in Saudi Arabia. Table 1 summarizes 
actions needed to tackle AMR in Saudi Arabia.
In conclusion, AMR is a global issue that requires 
tremendous attention. International agencies have 
suggested recommendations and plans to combat AMR. 
It is now up to countries to take the lead and implement 
local actions plans to limit AMR. Saudi Arabia faces 
several challenges that can stimulate the emergence 
and spread of MDR bacteria. These challenges require 
cultivated efforts from different sectors to successfully 
achieve a significant control of AMR in the country. 
Actions should include active surveillance of AMR 
on hospital-based, regional, and nationwide levels. 
Infection prevention and control precautions should 
also be optimized to limit the spread. Raising awareness 
of AMR is an essential mandate to limit inappropriate 
use of antibiotics, and the use of antimicrobial should 
be maintained by antibiotic stewardship programs not 
only in hospital settings, but also in outpatients and 
community pharmacies.
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PME-1-Producing Pseudomonas aeruginosa in Qatar
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The novel extended-spectrum -lactamase (ESBL) PME-1 wasfirst described in 2010 in an isolate from a Pseudomonas
aeruginosa strain obtained frommultiple clinical specimens from
a single patient admitted to the University of Pittsburgh Medical
Center in 2008. The patient had had a prolonged period of hospi-
talization in United Arab Emirates immediately before being
transferred to the United States (1).We describe here the first case
of P. aeruginosa carrying blaPME-1 isolated fromQatar and present
the second report to date of this enzyme.
The P. aeruginosaHZ-QTR-51 isolate was sent to the reference
laboratory at The University of Queensland Centre for Clinical
Research (UQCCR) as part of a region-wide collaborative study
onmultidrug-resistant Gram-negative bacilli (2, 3). The Etest was
used to measure the MIC of several antimicrobial compounds as
listed in Table 1.
The bacterial genomic DNAwas extracted using anUltraClean
Microbial DNA isolation kit (Mo Bio Laboratories). Species iden-
tification was performed using the PAduplex assay as previously
described (4). Paired-end libraries of whole genomic DNA of HZ-
QTR-51 were prepared via the use of a Nextera XT DNA sample
preparation kit and sequenced by the use of an Illumina HiSeq
platform (Illumina, San Diego, CA, USA). The 100-bp-paired-
end reads were de novo assembled using CLC Genomic Work-
bench with a minimum contig length of 200 bp. A total of 167
contigs were assembled with depth coverage of ca. 100.
The sequence type (ST) of P. aeruginosaHZ-QTR-51 was con-
firmed as ST 654 by in silico multilocus sequence typing (MLST)
(https://cge.cbs.dtu.dk/services/MLST/) (5). The ResFinder 2.1
platform (http://cge.cbs.dtu.dk/services/ResFinder/) (6) was also
used to characterize acquired antimicrobial resistancemechanism
genes among those in the draft genome. The isolate carried
blaPME-1 as well as blaOXA-50, blaGES-5, and blaPAO contributing to
-lactam resistance and strA, aph(3=)-VIa, aph(3=)-IIb, and strB
for aminoglycoside resistance. The isolate also carried fosA for
fosfomycin resistance, catB7 for chloramphenicol resistance, sul1
for sulfonamide resistance, and tet(A) and tet(G) for tetracycline
resistance. For further confirmation, blaPME-specific primers were
used as previously described (1).
P. aeruginosa HZ-QTR-51 was phenotypically resistant to all
tested antibiotics and was on the breakpoint border for amikacin
(Table 1). The carbapenem resistance in this isolate might be due
to the production of GES-5, which is a carbapenemase (7).
P. aeruginosa ST 654 is noteworthy for several reasons. VIM-
2-producing P. aeruginosa ST 654 was isolated from a patient in
Sweden following hospitalization in Tunisia (8). ST 654 was also
associated with KPC-producing P. aeruginosa fromArgentina (9).
More recently, VIM-2-producing P. aeruginosa ST 654 was iden-
tified among the international “high-risk clones” in the United
Kingdom (10). These reports highlight that P. aeruginosa ST 654 is
an internationally disseminated clone with a multidrug-resistant
phenotype, which might facilitate the rapid international spread
of PME-1 (and GES-5)-producing P. aeruginosa.
In conclusion, this report presents the first description of
PME-1-producing P. aeruginosa in Qatar and the second in the
world (11). The currently described P. aeruginosa isolate belongs
to successful international clone ST 654, which might contribute
to the global spread of multiple antibiotic resistance mechanisms,
including blaPME-1 and blaGES-5. We suggest active surveillance for
multidrug-resistant P. aeruginosa to assess the dissemination and
prevalence of beta-lactamase-mediated antibiotic resistance in the
Gulf region.
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TABLE 1 Antimicrobial MICs for PME-1-producing P. aeruginosa HZ-
QTR-51
Antimicrobial category Antimicrobial agent
MIC
(mg/liter)
EUCAST
interpretationa
Aminoglycosides Gentamicin 256 R
Amikacin 16 NS
Netilmicin 8 R
Antipseudomonal
penicillins and -
lactamase inhibitors
Ticarcillin/clavulanate 256 R
Piperacillin/tazobactam 32 R
Carbapenems Imipenem 32 R
Meropenem 32 R
Doripenem 32 R
Extended-spectrum
cephalosporins
Ceftazidime 32 R
Cefepime 16 R
Fluoroquinolones Ciprofloxacin 32 R
Monobactams Aztreonam 128 R
a R, resistant; NS, nonsusceptible.
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Differentiation of Acinetobacter Genomic Species 13BJ/14TU from
Acinetobacter haemolyticus by Use of Matrix-Assisted Laser
Desorption Ionization–Time of Flight Mass Spectrometry (MALDI-
TOF MS)
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Gulf Cooperation Council Center for Infection Control, Riyadh, Saudi Arabiac; Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailandd; Laboratory of
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Acinetobacter genomic species 13BJ and genomic species 14TUwere delineated independently in 1989 based on DNA-DNA
hybridization among proteolytic strains of human origin (1, 2).
Later studies suggested that these two taxa were congruent with
each other at the species level and represented a distinct phylo-
group within the hemolytic-proteolytic clade of the genus Acin-
etobacter (3). Reports from different countries showed that strains
of Acinetobacter genomic species 13BJ/14TU were found in clini-
cal specimens at a frequency similar to or even higher than that of
another hemolytic and proteolytic species, Acinetobacter haemo-
lyticus (4–6). It has also been noted that strains of Acinetobacter
genomic species 13BJ/14TU are intrinsically resistant to polymyx-
ins (4, 7), which further underpins the clinical relevance of this
taxon.
Previously, Acinetobacter genomic species 13BJ/14TU had not
been correctly identified using some phenotypic identification
systems and the VitekMS matrix-assisted laser desorption ioniza-
tion–time of flight (MALDI-TOF) microbial identification sys-
tem, although correct identification was achieved using partial
rpoB gene sequencing (4, 8). In the present study, we showed that
Acinetobacter genomic species 13BJ/14TU can be reliably differen-
tiated from other Acinetobacter species using MALDI-TOF mass
spectrometry (MS).
The strains of Acinetobacter genomic species 13BJ/14TU and A.
haemolyticus for this study were selected mostly from the collec-
tion of the Laboratory of Bacterial Genetics (National Institute of
Public Health, Prague, Czech Republic) and also included refer-
ence strains analyzed in the original DNA hybridization studies
(Table 1). The whole-genome sequences for seven of these refer-
ence strains were published recently (3, 9). The species identity of
the seven strains was confirmed by whole-genome sequence
comparison using average nucleotide identity based on BLAST
(ANIb), which was calculated using the JSpecies web program
(http://imedea.uib-csic.es/jspecies/) with the default setting (3).
The identification of the 13 remaining strains was based on a com-
bination of validated methods, including comparative analysis of
the partial rpoB gene, amplified rRNA gene restriction analysis
(ARDRA), and/or phenotypic analysis (5, 7). All strains were ep-
idemiologically unrelated as confirmed by their unique ApaI mac-
rorestriction profiles of their genomic DNA and/or differences in
their rpoB gene sequences (data not shown).
A subculture of each of the strains investigated was streaked
onto sheep blood agar (Difco Laboratories, Detroit, MI; 5% sheep
blood from Oxoid, Hampshire, United Kingdom) and incubated
at 37°C for 24 h. Cells from representative single bacterial colonies
were directly smeared onto a target spot of a steel target plate by
using a disposable loop, overlaid with 1 l of matrix consisting of
a saturated solution of sinapinic acid (catalog no. 49508; Sigma-
Aldrich, Buchs, Switzerland) in 60% acetonitrile (catalog no.
154601; Sigma-Aldrich)-3% trifluoroacetic acid (catalog no.
T6508; Sigma-Aldrich) or -cyano-4-hydroxycinnamic acid (cat-
alog no. 145505; Sigma-Aldrich, Buchs, Switzerland) in 33% eth-
anol-33% acetonitrile (catalog no. 154601; Sigma-Aldrich, Buchs,
Switzerland)–3% trifluoroacetic acid (catalog no. T6508; Sigma-
Aldrich), and air dried within minutes at room temperature. Ma-
trices were tested in parallel to assess the impact of matrices on the
ability to identify the strains.
Protein mass fingerprints were obtained using a MALDI-TOF
Axima Confidence mass spectrometer (Shimadzu-Biotech Corp.,
Kyoto, Japan), with detection in the linear, positive mode at a laser
frequency of 50 Hz and within a mass range of 3,000 to 30,000 Da.
Acceleration voltage was 20 kV, and the extraction delay time was
200 ns. For each sample spot, a total of 100 spectral profiles, each
consisting of 10 single spectra, were averaged and processed using
Launchpad v.2.8 software (Shimadzu-Biotech Corp., Kyoto, Ja-
pan). This software was also used for peak processing of all raw
spectra with the following settings: the advanced scenario was
chosen from the Parent Peak Cleanup menu, peak width was set at
80 channels, the smoothing filter width was set at 50 channels, the
baseline filter width was set at 500 channels, and for peak detection
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method, the threshold apex was chosen. For the threshold apex
peak detection, the threshold type was set as dynamic and the
threshold offset was set to 0.025 mV with a threshold response
factor of 1.25. The processed spectra were exported as peak lists
with m/z values and signal intensities for each peak in the ASCII
format. Calibration was conducted for each target plate using
spectra of the reference strain Escherichia coli DH5.
All 21 strains were analyzed in duplicate using two sample
spots from the same colony. Generated protein mass fingerprints
were analyzed with SARAMIS software (AnagnosTec, Potsdam-
Golm, Germany) and the Putative Assigned Protein Masses for
Identification Database (PAPMID) (Mabritec, Switzerland).
In the first step, a biomarker mass pattern, called a superspec-
trum, was calculated for the Acinetobacter genomic species 13BJ/
14TU, using the SARAMIS SuperSpectrum tool. As ribosomes are
known to be among the most abundant proteins (10), 23 ribo-
somal subunit protein masses, namely, L36 (4,265.1 Da), L34
(5,175.1 Da), L33 (6,104.3 Da), L30 (6,641.7 Da), L32 (6,930.8
Da), L35 (7,185.8 Da), L29 (7,448.6 Da), L31 (8,343.6 Da), S21
(8,349.9 Da), L27 (8,769.1 Da), L28 (8,986.7 Da), S17 (9,407.0
Da), S20 (9,570.2 Da), S15 (10,007.5 Da), S19 (10,063.9 Da), S14
(11,253.2 Da), L18 (12,390.1 Da), L17 (13,540.7 Da), S12
(13,649.0 Da), L13 (15,859.3 Da), S5 (17,008.7 Da), S7 (17,554.5
Da), and L6 (18,968.0 Da), were retrieved from the genome of
Acinetobacter genomic species 13BJ/14TU strain CIP 64.2, making
use of the PAPMID software. The spectra of the Acinetobacter
genomic species 13BJ/14TU strains investigated in this study were
matched against these reference masses for automatic identifica-
tion, allowing for an error of 500 ppm.
The superspectrum for automated identification of Acineto-
bacter genomic species 13BJ/14TU was generated according to the
user guidelines and validated against the entire in-house extended
SARAMIS database (version 3.3.2), consisting of 2,087 bacterial
species, including 18 Acinetobacter spp. with validly published
names. These 18 species encompass all Acinetobacter spp. which
are known to be associated with human clinical specimens, except
for Acinetobacter nosocomialis, Acinetobacter seifertii, Acinetobac-
ter soli, and Acinetobacter variabilis.
All 21 strains were identified using SARAMIS software, includ-
ing the new Acinetobacter genomic species 13BJ/14TU superspec-
trum. Using only the SARAMIS database without the new Acin-
etobacter genomic species 13BJ/14TU superspectrum, all 10 A.
haemolyticus strains were identified correctly as A. haemolyticus
while the 11 Acinetobacter genomic species 13BJ/14TU strains had
been identified only as Acinetobacter spp. However, with the im-
plementation of the Acinetobacter genomic species 13BJ/14TU su-
perspectrum, all strains were correctly identified as A. haemolyti-
cus or Acinetobacter genomic species 13BJ/14TU, respectively. The
choice of matrix used for spectral acquisition made no impact on
the identification of the strains.
MALDI-TOF MS, as we have demonstrated, is a useful tool in
the differentiation and identification of related species of bacteria
such as A. haemolyticus and Acinetobacter genomic species 13BJ/
14TU. Other studies detailing the use of a commercial MALDI
mass spectrometer in comparison with other instruments such as
the Vitek 2 and MicroScan reported that Acinetobacter genomic
species 13BJ/14TU could not be accurately identified with these
instruments (8). However, the method used here uses the same
principle as commercial instruments used in routine identifica-
tion procedures but with a more in-depth approach in the analysis
of the spectra.
The use of calculated theoretical masses from sample genomes
as identifying masses contributed to the improved discriminatory
power of our method as observed in this study. Use of a sinapinic
acid matrix may further increase the discriminatory power of the
method due to its ability to better ionize proteins of higher mo-
lecular weights that can be used for identification compared to
-cyano-4-hydroxycinnamic acid (11, 12).
TABLE 1 Strains used in this study
Strain Species Country, yr of isolation
Specimen
(human)
WGSa accession
no. Reference(s)
CIP 64.3T A. haemolyticus Unknown Sputum APQQ00000000.1 3, 13
NIPH 1878 (Tjernberg 197) A. haemolyticus Sweden, 1980s Wound 2
NIPH 58 A. haemolyticus Czech Republic, 1992 Blood 5
NIPH 261 A. haemolyticus Czech Republic, 1993 Tissue APQR00000000.1 3, 5
NIPH 939 A. haemolyticus Czech Republic, 1998 Cervix 5
ANC 3857 A. haemolyticus Czech Republic, 2010 Wound
ANC 3923 A. haemolyticus Czech Republic, 2010 Wound
ANC 3927 A. haemolyticus Czech Republic, 2010 Wound
ANC 4581 (CIP 70.27) A. haemolyticus Unknown Nose ADMT00000000.1 9, 13
ANC 4583 (CIP 70.26) A. haemolyticus Unknown Ocular pus AMJB00000000.1 9, 13
NIPH 1860 (CIP 64.2) Acinetobacter genomic species 13BJ/14TU Germany Conjunctiva APRT00000000.1 1, 2, 3
NIPH 1859 (Tjernberg 71) Acinetobacter genomic species 13BJ/14TU Sweden, 1980s Conjunctiva APRZ00000000.1 2, 3
NIPH 1861 (Bouvet 496) Acinetobacter genomic species 13BJ/14TU France Skin 1
NIPH 2036 (Bouvet 1191) Acinetobacter genomic species 13BJ/14TU Belgium Catheter ATGK00000000.1 1, 3
ANC 3881 Acinetobacter genomic species 13BJ/14TU Czech Republic, 2010 Lungs (autopsy)
NIPH 378 Acinetobacter genomic species 13BJ/14TU Czech Republic, 1995 Eye 5
NIPH 637 Acinetobacter genomic species 13BJ/14TU Czech Republic, 1995 Blood 5
NIPH 669 Acinetobacter genomic species 13BJ/14TU Czech Republic, 1997 Blood 5
NIPH 1035 Acinetobacter genomic species 13BJ/14TU Czech Republic, 1998 Blood 5
ANC 4056 Acinetobacter genomic species 13BJ/14TU Germany, 2004 Wound
J80 Acinetobacter genomic species 13BJ/14TU Japan Unknown
a WGS, whole-genome sequence.
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